

CITATION REPORT

List of articles citing

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

DOI: 10.1016/s0140-6736(16)32517-x
Lancet, The, 2017, 389, 255-265.

Source: <https://exaly.com/paper-pdf/66773415/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2214	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. 2017 , 5, 106-117		162
2213	Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. 2017 , 18, 444-459.e1		56
2212	The safety of second-line treatment options for non-small cell lung cancer. 2017 , 16, 471-479		2
2211	Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective. 2017 , 31, e407-e408		6
2210	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. 2017 , 5, 312-318		259
2209	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. 2017 , 10, 64		20
2208	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. 2017 , 18, 572-582.e1		39
2207	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. 2017 , 44, 41-54		35
2206	Novel immune checkpoint blocker to treat Merkel cell carcinoma. 2017 , 6, e1315496		1
2205	Immune checkpoint inhibitors in lung cancer: an update. 2017 , 13, 955-959		4
2204	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. 2017 , 152, 271-281		249
2203	Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?. 2017 , 79, 149-151		8
2202	PD1 functions by inhibiting CD28-mediated co-stimulation. 2017 , 6, e138		7
2201	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. 2017 , 18, 682-691.e5		57
2200	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. 2017 , 9, 507-520		8
2199	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. 2017 , 195, 1150-1160		57
2198	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. 2017 , 11, 469-479		9

2197	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. 2017 , 56, 651-659	30
2196	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. 2017 , 26, 1139-1145	52
2195	The next generation of immunotherapy: keeping lung cancer in check. 2017 , 10, 87	63
2194	U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. 2017 , 23, 4534-4539	84
2193	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. 2017 , 14, 1248-1260	10
2192	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. 2017 , 3, e171029	46
2191	Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?. 2017 , 125, 591-593	3
2190	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. 2017 , 12, 563-569	50
2189	Immunogenomics: using genomics to personalize cancer immunotherapy. 2017 , 471, 209-219	5
2188	Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. 2017 , 376, 2483-2485	22
2187	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. 2017 , 12, 301-308	47
2186	Correlation of immune phenotype with IDH mutation in diffuse glioma. 2017 , 19, 1460-1468	144
2185	Immunological effect of local ablation combined with immunotherapy on solid malignancies. 2017 , 36, 49	16
2184	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. 2017 , 18, 33	9
2183	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. 2017 , 18, 36	14
2182	Clinical applications of PD-L1 bioassays for cancer immunotherapy. 2017 , 10, 110	51
2181	Combining radiotherapy with immunotherapy: the past, the present and the future. 2017 , 90, 20170157	60
2180	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. 2017 , 109, 101-108	24

2179	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. 2017 , 3,	16
2178	Understanding the checkpoint blockade in lung cancer immunotherapy. 2017 , 22, 1266-1273	36
2177	Scientific Advances in Thoracic Oncology 2016. 2017 , 12, 1183-1209	29
2176	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. 2017 , 17, 647-655	10
2175	Learning from Failure; Hypoxia Is an Evil Foe. 2017 , 58, 1043-1044	4
2174	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. 2017 , 18, 556-557	18
2173	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. 2017 , 15, 55	43
2172	Atezolizumab-induced Encephalitis in Metastatic Bladder Cancer: A Case Report and Review of the Literature. 2017 , 15, e847-e849	19
2171	Prospects and progress of atezolizumab in non-small cell lung cancer. 2017 , 17, 781-789	11
2170	Pembrolizumab for the treatment of non-small cell lung cancer. 2017 , 17, 399-409	24
2169	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. 2017 , 16, 573-585	16
2168	Immunotherapy: Benefit with anti-PD-L1. 2017 , 14, 70-71	0
2167	S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?. 2017 , 28, 2627-2629	0
2166	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. 2017 , 12, 1798-1805	241
2165	PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. 2017 , 51, 357-362	28
2164	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. 2017 , 2, e000236	19
2163	PD-L1 IHC in NSCLC with a global and methodological perspective. 2017 , 113, 102-105	25
2162	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39	29

2161	Atezolizumab in invasive and metastatic urothelial carcinoma. 2017 , 10, 1295-1301	8
2160	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. 2017 , 7, 1420-1435	302
2159	Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. 2017 , 96, 378-383	55
2158	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
2157	[Lung cancer : What has been confirmed in therapy?]. 2017 , 58, 1258-1263	1
2156	Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. 2017 , 1868, 571-583	34
2155	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. 2017 , 3, 360-373	7
2154	Current chemotherapeutic regimens for brain metastases treatment. 2017 , 34, 391-399	5
2153	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. 2017 , 86, 257-265	21
2152	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). 2017 , 28, 2698-2706 ⁵¹	
2151	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. 2017 , 28, 3044-3050	87
2150	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. 2017 , 18, 1477-1490	16
2149	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. 2017 , 11, 353-373	19
2148	New Immunotherapy and Lung Cancer. 2017 , 53, 682-687	6
2147	Lung Cancer in the Older Patient. 2017 , 33, 563-577	13
2146	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. 2017 , 377, 849-861	376
2145	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. 2017 , 117, 913-920	111
2144	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. 2017 , 12, 709-718	13

2143	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53
2142	A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002). 2017 , 80, 955-963	10
2141	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. 2017 , 9, 913-927	24
2140	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. 2017 , 85, 155-157	5
2139	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. 2017 , 57 Suppl 10, S26-S42	63
2138	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. 2017 , 60, 60-68	83
2137	PD-1 checkpoint inhibition: Toxicities and management. 2017 , 35, 701-707	44
2136	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. 2017 , 35, 1195-1209	14
2135	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. 2017 , 23, 4959-4969	71
2134	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. 2017 , 23, 4992-5002	26
2133	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. 2017 , 22, 213-222	5
2132	Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. 2017 , 40, 435-439	7
2131	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. 2017 , 38, 1512-1520	35
2130	Atezolizumab for the treatment of non-small cell lung cancer. 2017 , 10, 935-945	21
2129	The Current Role of Whole Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients. 2017 , 12, 1467-1477	16
2128	Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. 2017 , 111, 182-189	20
2127	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	14
2126	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. 2017 , 14, 1568-1580	8

2125	Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. 2017 , 31, 56-61	12
2124	Cancer Immunotherapies: Are They as Effective in the Elderly?. 2017 , 34, 567-581	22
2123	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. 2017 , 6, e1356145	177
2122	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. 2017 , 19, 62	11
2121	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. 2017 , 7, 5532	96
2120	Checkpoint inhibitors in the treatment of urological malignancies. 2017 , 2, e000165	15
2119	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. 2017 , 2, e000200	25
2118	The importance for immunoregulation for long-term cancer control. 2017 , 13, 1619-1632	8
2117	Lung cancer as a cardiotoxic state: a review. 2017 , 34, 159	7
2116	Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. 2017 , 11, 791-805	2
2115	Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. 2017 , 32, 300-312	35
2114	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. 2017 , 44, 2310-2325	34
2113	Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer. 2017 , 114, 106-107	7
2112	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. 2017 , 112, 90-95	128
2111	PD-L1-Hemmer beim NSCLC von Nutzen. 2017 , 20, 23-23	
2110	[Current Aspects of Diagnosis and Treatment of Lung Cancer]. 2017 , 142, 1808-1812	3
2109	New Immunotherapy and Lung Cancer. 2017 , 53, 682-687	3
2108	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. 2017 , 2, 235-244	2

2107	Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?. 2017 , 13, 2503-2505	7
2106	Personalised medicine for nonsmall cell lung cancer. 2017 , 26,	28
2105	Cardiotoxicity of immune checkpoint inhibitors. 2017 , 2, e000247	126
2104	Checkpointinhibitoren. 2017 , 23, 619-625	
2103	Immune checkpoint inhibitors and elderly people: A review. 2017 , 82, 155-166	99
2102	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. 2017 , 405, 29-37	51
2101	Biomarkers of response to PD-1/PD-L1 inhibition. 2017 , 116, 116-124	185
2100	Zweitlinientherapie mit Atezolizumab verlangert das erleben. 2017 , 20, 19-20	
2099	Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C. 2017 , 20, 32-42	
2098	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. 2017 , 5,	8
2097	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. 2017 , 209, 567-575	22
2096	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmler and Alberto Cavazza. 2017 , 26,	49
2095	Immuncheckpointinhibitoren. 2017 , 23, 575-584	
2094	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. 2017 ,	78
2093	Report on the Third FDA-AACR Oncology Dose-Finding Workshop. 2017 , 5, 1058-1061	0
2092	ASCO update: lung cancer. 2017 , 10, 224-227	12
2091	Prise en charge des patients de stade avanc avec remaniement ALK : aujourdhui et demain (« qui sera un autre jour... »). 2017 , 9, 224-233	
2090	Traitement de premire ligne et de maintenance dans les CBNPC avancs en labsence daddiction oncognique. 2017 , 9, 234-247	

2089	Cancer bronchique non ^petites cellules de stade IV sans addiction oncoghique : traitements en 2 e ligne et au-del^.	2017, 9, 248-258	
2088	Mfastases cfbrales des cancers bronchiques non ^petites cellules (CBNPC).	2017, 9, 271-287	
2087	Les patients avec indice de performance supfieur ^1.	2017, 9, 308-314	
2086	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.	2017, 9, 769-779	9
2085	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomenigeal metastasis from solid tumours.	2017, 28, iv84-iv99	157
2084	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.	2017, 6, 93-107	3
2083	ESMO Copenhagen 2016: a lung cancer 'grand cru'.	2017, 2, e000196	
2082	Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom.	2017, 23, 838-844	
2081	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy.	2017, 1, 7-7	11
2080	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy.	2017, 1,	1
2079	Cancer Immunotherapy in Older Patients.	2017, 23, 219-222	4
2078	Clinical use of immune checkpoint inhibitors.	2017,	
2077	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.	2017, 11, 787	24
2076	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.	2017, 8, 49	314
2075	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.	2017, 8, 730	233
2074	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.	2017, 8, 67-78	20
2073	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.	2017, 10, 2097-2106	32
2072	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.	2017, 17, 378-391	50

2071	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
2070	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. 2017 , 18,	60
2069	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. 2017 , 8, 1597	145
2068	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. 2017 , 18,	34
2067	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. 2017 , 8, 961	70
2066	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. 2017 , 8, 1547	80
2065	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. 2017 , 7, 67	25
2064	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. 2017 , 7, 197	18
2063	CD80 Expressed by CD8 T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 T Cells. 2017 , 2017, 7659462	21
2062	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. 2017 , 2017, 5618174	8
2061	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. 2017 , 2017, 1750925	31
2060	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. 2017 , 9, 147-157	3
2059	Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. 2017 , 9, 601-609	15
2058	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. 2017 , 8, 48248-48252	65
2057	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2017 , 8, 93149-93155	45
2056	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. 2017 , 8, 66491-66503	1
2055	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. 2017 , 9, 2560-2571	16
2054	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. 2017 , 13,	

2053	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. 2017 , 12, e0181598	25
2052	PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. 2017 , 12, e0182692	125
2051	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421	31
2050	TBP-Konzept auch in der Immunonkologie?. 2017 , 9, 63-63	
2049	Auch bei Lungenkrebs eine neue Option. 2017 , 9, 65-65	
2048	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. 2017 , 10, 136	33
2047	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. 2017 , 10, 174	68
2046	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 2017 , 5, 66	27
2045	Immuntherapie thorakaler Tumoren. 2017 , 20, 21-27	
2044	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. 2017 , 8, 66293-66304	8
2043	The combination of checkpoint immunotherapy and targeted therapy in cancer. 2017 , 5, 388	45
2042	Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. 2017 , 8, 58199-58209	9
2041	Atezolizumab in advanced non-small cell lung cancer. 2017 , 9, 3603-3606	6
2040	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. 2017 , 9, E384-E386	14
2039	Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. 2017 , 8, 4075-4082	7
2038	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. 2017 , 1,	16
2037	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). 2017 , 35, 2781-2789	248
2036	Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. 2017 , 35, 2735-2736	2

2035	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 2017 , 35, 3924-3933	495
2034	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. 2017 , 35, 3867-3876	263
2033	Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. 2017 , 37, 630-639	7
2032	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. 2017 , 13, 832-837	37
2031	How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?. 2017 , 35, 2860-2862	
2030	A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC. 2017 , 9, E292-E294	
2029	PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies. 2017 , 9, E470-E473	3
2028	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. 2017 , 9, 2142-2158	62
2027	KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer. 2017 , 9, 4187-4190	2
2026	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. 2017 , 6, 570-587	26
2025	Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. 2017 , 6, S35-S38	6
2024	Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them. 2017 , 6, S51-S54	7
2023	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. 2017 , 6, S41-S43	2
2022	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. 2017 , 1, 1-15	31
2021	Oncogenic pathways as the basis of primary immune ignorance. 2017 , 1, 421-428	
2020	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. 2018 , 4, 522-528	56
2019	Targeting the microenvironment in solid tumors. 2018 , 65, 22-32	189
2018	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. 2018 , 73, 800-806	16

2017	Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?. 2018 , 10, 403-410	5
2016	Time is up for PD-L1 testing standardization in lung cancer. 2018 , 29, 791-792	2
2015	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. 2018 , 29, 1320-1324	21
2014	Promises and challenges of immuno-oncology from a clinical perspective. 2018 , 48, 101-102	1
2013	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. 2018 , 23, 410-420	40
2012	Immunotherapy in Lung Cancer and the Role of Imaging. 2018 , 39, 314-321	2
2011	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. 2018 , 12, 1179554918759079	4
2010	Cancer immunotherapy in patients with brain metastases. 2018 , 67, 703-711	11
2009	Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. 2018 , 41, 1113-1117	3
2008	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. 2018 , 126, 342-352	81
2007	Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2018 , 19, 352-359.e1	7
2006	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. 2018 , 119, 14-20	85
2005	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. 2018 , 233, 6337-6343	65
2004	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. 2018 , 120, 137-141	22
2003	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. 2018 , 24, 3292-3298	22
2002	Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. 2018 , 57, 1225-1231	42
2001	Atezolizumab for the treatment of breast cancer. 2018 , 18, 595-603	12
2000	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. 2018 , 3, e000344	60

1999	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. 2018 , 378, 1976-1986	865
1998	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. 2018 , 378, 2078-2092	2820
1997	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. 2018 , 10, 1758835918768238	39
1996	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. 2018 , 10, 1758835918762094	74
1995	PD-L1 expression testing in non-small cell lung cancer. 2018 , 10, 1758835918763493	90
1994	The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. 2018 , 482, 101-107	26
1993	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. 2018 , 19, e421-e430	28
1992	Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. 2018 , 56, 485-495	42
1991	Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. 2018 , 117, 1563-1569	15
1990	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. 2018 , 120, 62-69	18
1989	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. 2018 , 10, 1758835918763723	2
1988	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. 2018 , 66, 114-121	25
1987	NSCLC: State of the Art Diagnosis, Treatment, and Outcomes. 2018 , 7, 29-41	2
1986	Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?. 2018 , 7, 42-48	
1985	Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. 2018 , 19, 2098-2108	46
1984	Anti-Angiogenics: Their Value in Lung Cancer Therapy. 2018 , 41, 172-180	22
1983	Emerging landscape of circular RNAs in lung cancer. 2018 , 427, 18-27	74
1982	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. 2018 , 11, 475-486	52

1981	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. 2018 , 10, 1758835918763744	17
1980	Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. 2018 , 51,	7
1979	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 13, 323-358	241
1978	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. 2018 , 118, 36-40	51
1977	Combining chemotherapy with PD-1 blockade in NSCLC. 2018 , 186, 130-137	56
1976	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. 2018 , 126, 253-263	55
1975	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. 2018 , 64, 21-29	31
1974	[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]. 2018 , 35, 197-205	3
1973	[The biological rationale for immunotherapy in cancer]. 2018 , 35, 206-222	4
1972	Immuno-oncology-101: overview of major concepts and translational perspectives. 2018 , 52, 1-11	30
1971	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 2018 , 13, 1-20	23
1970	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. 2018 , 29, i20-i27	54
1969	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 142, 321-346	371
1968	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers. 2018 , 24, 1954-1964	40
1967	Role of immune-checkpoint inhibitors in lung cancer. 2018 , 12, 1753465817750075	58
1966	Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. 2018 , 29, 953-958	133
1965	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β . 2018 , 10,	239
1964	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. 2018 , 14, 191-194	3

1963	Established, emerging and elusive molecular targets in the treatment of lung cancer. 2018 , 244, 565-577	11
1962	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. 2018 , 4, 537-544	82
1961	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 20, 129-159	165
1960	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. 2018 , 6, 402-408	42
1959	Translation in Immunology. 2018 , 1-11	
1958	Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer. 2018 , 53, 1205-1213	6
1957	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. 2018 , 24, 1271-1276	24
1956	PD-1/PD-L1 Axis in Lung Cancer. 2018 , 24, 15-19	39
1955	The biology and management of non-small cell lung cancer. 2018 , 553, 446-454	1499
1954	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. 2018 , 18, 267-276	11
1953	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2018 , 19, 301-314	6
1952	PD-1/PD-L1 in disease. 2018 , 10, 149-160	47
1951	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. 2018 , 19, 280-288.e4	38
1950	[Atezolizumab (Tecentriq): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]. 2018 , 105, 140-145	10
1949	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. 2018 , 100, 916-925	162
1948	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. 2018 , 13, 165-183	52
1947	Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. 2018 , 13, 377-386	39
1946	Progress in the Management of Advanced Thoracic Malignancies in 2017. 2018 , 13, 301-322	34

1945	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 748-757	40	753
1944	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 106-111		130
1943	Immune Checkpoint Inhibition in Lung Cancer. 2018 , 333-344		
1942	Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. 2018 , 19, 345-361		251
1941	Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer. 2018 , 105, 448-454		12
1940	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. 2018 , 126, 217-223		67
1939	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. 2018 , 4, 210-216		277
1938	Will liquid biopsies become our fluid transition to personalized immunotherapy?. 2018 , 29, 11-13		1
1937	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). 2018 , 10, 1758834017745012		73
1936	Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors. 2018 , 25, 339-350		27
1935	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2018 , 19, e335-e348		39
1934	Inhibitors of the PD-1 Pathway in Tumor Therapy. 2018 , 200, 375-383		82
1933	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. 2018 , 116, 1-6		35
1932	High response rate to PD-1 blockade in desmoplastic melanomas. 2018 , 553, 347-350		178
1931	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. 2018 , 4, 351-357		357
1930	The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. 2018 , 142, 2344-2354		35
1929	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. 2018 , 33, 62-68		4
1928	The Basics of Cancer Immunotherapy. 2018 ,		2

1927	Significance of Immune Checkpoints in Lung Cancer. 2018 , 59-77	
1926	Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer. 2018 , 30, 98-104	3
1925	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. 2018 , 360, k793	262
1924	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. 2018 , 24, 3857-3866	97
1923	CIMAvax-EGF: Toward long-term survival of advanced NSCLC. 2018 , 45, 34-40	10
1922	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. 2018 , 18, 302	13
1921	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. 2018 , 6, 26	89
1920	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. 2018 , 13, 1128-1137	84
1919	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. 2018 , 6, 15	13
1918	Therapeutic antibodies: A new era in the treatment of respiratory diseases?. 2018 , 189, 149-172	18
1917	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. 2018 , 7, e1448332	34
1916	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. 2018 , 38, 1063-1078	164
1915	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. 2018 , 13, 1037-1042	58
1914	Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer. 2018 , 7, e1457600	14
1913	Recent progress in systemic treatment for lung cancer. 2018 , 24, 355-366	7
1912	Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. 2018 , 101, 624-629	67
1911	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. 2018 , 13, 831-839	57
1910	PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4 T Cell Adoptive Immunotherapy. 2018 , 200, 3304-3311	4

1909	Liquid Biopsies and Cancer Immunotherapy. 2018 , 24, 78-83	12
1908	Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. 2018 , 97, e9617	37
1907	Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma. 2018 , 19, e551-e558	7
1906	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. 2018 , 11, 17562864187596183	3
1905	Phase Ib Study of Baviximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2018 , 19, e481-e487	10
1904	[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists]. 2018 , 38, 110-125	14
1903	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. 2018 , 13, 926-937	17
1902	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. 2018 , 19, 331-339	13
1901	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. 2018 , 9, 451-458	11
1900	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. 2018 , 10, 643-655	9
1899	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. 2018 , 94, 179-186	53
1898	Biomarker use in lung cancer management: expanding horizons. 2018 , 12, 315-320	0
1897	Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. 2018 , 19, e405-e415	36
1896	Targeting immune checkpoints in non small cell lung cancer. 2018 , 40, 46-50	36
1895	Genomic Testing in Lung Cancer: Past, Present, and Future. 2018 , 16, 323-334	17
1894	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 2018 , 19, 521-536	315
1893	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. 2018 , 9, 494-500	12
1892	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. 2018 , 48, 1-8	44

1891	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. 2018 , 8,	8
1890	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. 2018 , 71, 46-51	16
1889	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. 2018 , 142, 408-419	52
1888	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. 2018 , 19, 1-11	34
1887	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. 2018 , 29, 193-199	111
1886	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. 2018 , 13, 33-42	2
1885	Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. 2018 , 24, 407-419	124
1884	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. 2018 , 29, 71-83	154
1883	Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. 2018 , 142, 1277-1284	55
1882	Atezolizumab-Induced New Onset Diabetes Mellitus With Ketoacidosis. 2018 , 25, e565-e568	4
1881	Immunotherapy as an Option for Cancer Treatment. 2018 , 66, 89-96	13
1880	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. 2017 , 7, e1376156	11
1879	Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab. 2018 , 19, e171-e176	40
1878	Immune checkpoint blockade in infectious diseases. 2018 , 18, 91-104	242
1877	The application and mechanism of PD pathway blockade for cancer therapy. 2018 , 94, 53-60	9
1876	Immunotherapy and Lung Cancer. 2018 , 501-511.e3	2
1875	Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. 2018 , 72, 449-459	54
1874	Lung cancer epigenetics: From knowledge to applications. 2018 , 51, 116-128	142

1873 Hiding from the good guys. **2018**, 155, 363-364

1872 Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. **2018**, 13, 124-133 35

1871 Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. **2018**, 18, 63-70 89

1870 Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. **2018**, 57, 705-708 25

1869 Durvalumab in non-small-cell lung cancer patients: current developments. **2018**, 14, 205-222 7

1868 Molecular Diagnosis and Targeting for Lung Cancer. **2018**, 1-32

1867 Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. **2018**, 88, 38-47 178

1866 High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. **2018**, 67, 495-505 10

1865 Product review on the Anti-PD-L1 antibody atezolizumab. **2018**, 14, 269-276 22

1864 Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. **2018**, 115, 84-88 29

1863 Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. **2018**, 67, 471-481 4

1862 Immunotherapeutic Biomarkers and Selection Strategies. **2018**, 69-114

1861 Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. **2018**, 7, e1396403 34

1860 The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. **2018**, 19, 120-129 48

1859 Early Phase Cancer Immunotherapy. **2018**, 1

1858 Thoracic Immunotherapy. **2018**, 281-305

1857 Combinatorial Immunotherapy and Chemotherapy. **2018**, 199-218 4

1856 Immune checkpoint inhibitors: new strategies to checkmate cancer. **2018**, 191, 133-148 48

1855	PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. 2018 , 62, 39-49	67
1854	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. 2018 , 115, 12-20	98
1853	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. 2018 , 414, 166-173	132
1852	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. 2018 , 52, 166-177	8
1851	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. 2018 , 22, 1-10	89
1850	Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis. 2018 , 12, 1809-1819	18
1849	Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer. 2018 , 19, e177-e184	5
1848	Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. 2018 , 7, 404-415	46
1847	The role of immune checkpoint inhibitors in non-small cell lung cancer. 2018 , 2, 35-35	
1846	Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy. 2018 , 14, 537-538	6
1845	Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?. 2018 , 14, e375-e383	8
1844	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. 2018 , 38, 400-414	37
1843	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. 2018 , 36, 1905-1912	189
1842	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. 2018 , 36, 1675-1684	381
1841	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. 2018 , 36, 2872-2878	477
1840	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. 2018 , 36, 850-858	184
1839	Immune Checkpoint Inhibitors in the Management of Lung Cancer. 2018 , 38, 682-695	17
1838	Tumor Mutation Burden: Is It Ready for the Clinic?. 2018 , 36, 2978-2979	11

1837	Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?. 2018 , 10, S3203-S3206	4
1836	Lung cancer in never smokers-the East Asian experience. 2018 , 7, 450-463	47
1835	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. 2018 , 15, 434-442	16
1834	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?. 2018 , 7, 682-690	17
1833	Immunotherapy in treatment naïve advanced non-small cell lung cancer. 2018 , 10, S412-S421	8
1832	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. 2018 , 10, S3162-S3165	
1831	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. 2018 , 7, 647-660	50
1830	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. 2018 , 10, S4034-S4037	3
1829	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. 2018 , 7, 691-702	3
1828	Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer. 2018 , 7, S377-S380	3
1827	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). 2018 , 9, 17554-17563	16
1826	Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. 2018 , 10, 25-29	3
1825	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. 2018 , 10, 219-227	4
1824	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. 2018 , 10, S1516-S1533	36
1823	Immunotherapy in surgically resectable non-small cell lung cancer. 2018 , 10, S404-S411	41
1822	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. 2018 , 10, S451-S459	22
1821	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. 2018 , 10, 816-824	5
1820	Do immune checkpoint inhibitors need new studies methodology?. 2018 , 10, S1564-S1580	35

1819	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). 2018 , 10, S422-S432	6
1818	Oncogene-addicted non-small cell lung cancer and immunotherapy. 2018 , 10, S1547-S1555	24
1817	Current PD-L1 immunohistochemistry for non-small cell lung cancer. 2018 , 10, 1217-1219	15
1816	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. 2018 , 10, S995-S998	1
1815	The evolving understanding of immunoediting and the clinical impact of immune escape. 2018 , 10, 1248-1252	8
1814	Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. 2018 , 10, S1534-S1546	5
1813	Immunotherapy in the Asiatic population: any differences from Caucasian population?. 2018 , 10, S1482-S1493	23
1812	Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics. 2018 , 7, S39-S45	5
1811	Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. 2018 , 7, S91-S94	14
1810	Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?. 2018 , 7, S153-S157	1
1809	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. 2018 , 7, 464-486	8
1808	Advanced non-small cell lung cancer: the role of PD-L1 inhibitors. 2018 , 10, S1468-S1473	9
1807	Immune checkpoint inhibitors and small cell lung cancer: what's new?. 2018 , 10, S1503-S1508	11
1806	Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study. 2018 , 10, S1108-S1112	13
1805	PD-L1 immunohistochemistry in patients with non-small cell lung cancer. 2018 , 10, S2127-S2129	4
1804	Atezolizumab in non-squamous non-small cell lung cancer. 2018 , 10, S3155-S3159	4
1803	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. 2019 , 8, 107-115	22
1802	Pembrolizumab in patients with thymic carcinoma: a cautionary tale. 2018 , 2, 55-55	1

1801	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. 2018 , 10, S4082-S4084	0
1800	PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. 2018 , 7, S283-S286	1
1799	A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer. 2018 , 97, e13112	9
1798	Histology versus cytology: PD-L1 testing in non-small cell lung cancer. 2018 , 7, S225-S227	4
1797	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. 2018 , 10, S4069-S4072	1
1796	Quality of life for non-small cell lung cancer patients in the age of immunotherapy. 2018 , 7, S149-S152	10
1795	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. 2018 , 7, S290-S293	0
1794	The clinical utility of tumor mutational burden in non-small cell lung cancer. 2018 , 7, 639-646	61
1793	Foreground Detection with Deeply Learned Multi-Scale Spatial-Temporal Features. 2018 , 18,	9
1792	Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. 2019 , 17, 1349-1356	19
1791	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. 2018 , 7, LMT07	1
1790	Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. 2019 , 17, 1019-1029	4
1789	Immunotherapy in Advanced Lung Cancer Treatment. 2018 ,	
1788	Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients. 2019 , 17, 201-208	4
1787	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. 2018 , 14, 529-535	17
1786	The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. 2018 , 9, 4239-4248	10
1785	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. 2018 , 52, 365-369	27
1784	Vorteil unabhängig vom PD-L1-Status. 2018 , 10, 50-50	

1783	Zum Lungenkrebs informiert und vernetzt. 2018 , 10, 66-66	
1782	Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter. 2018 , 10, 34-42	
1781	Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report. 2018 , 97, e13739	2
1780	Lungen- und Urothelkarzinom. PD-L1-Blockade mit Atezolizumab: Überzeugend wirksam bei jedem PD-L1-Status. 2018 , 41, 64-65	2
1779	Medikamentöse Therapie des metastasierten oder rezidierten mutationsnegativen NSCLC. 2018 , 24, 1003-1008	0
1778	Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. 2018 , 13, e0206370	37
1777	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. 2018 , 363, k4226	191
1776	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. 2018 , 18, 1082	29
1775	Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells. 2018 , 7, 6051-6063	20
1774	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. 2018 , 10, 1303-1313	1
1773	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. 2018 , 16, 328	7
1772	and in the genetic landscape of immunotolerance in lung cancer. 2018 , 9, 35603-35604	2
1771	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. 2018 , 6, 126	17
1770	A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer. 2018 , 10, 5531-5537	1
1769	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. 2018 , 11, 7529-7542	20
1768	Lung cancer, elderly and immune checkpoint inhibitors. 2018 , 10, S1474-S1481	17
1767	Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. 2018 , 10, 1189-1192	21
1766	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. 2017 , 17, 527-540	14

1765	FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. 2018 , 45, 220-225	48
1764	Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. 2018 , 25, e373-e384	61
1763	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. 2018 , 9, 4664	202
1762	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. 2018 , 19, 2055-2062	18
1761	Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. 2018 , 10, 5178-5183	1
1760	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. 2018 , 9, 3158	41
1759	Actualit� et perspectives concernant lâimmunoth�rapie en oncologie thoracique. 2018 , 105 Suppl 1, S16-S23	
1758	Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. 2018 , 11, 8623-8632	8
1757	Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 2018 , 9, 5361	145
1756	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. 2018 , 11, 8565-8573	7
1755	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. 2018 , 9, 1430	54
1754	Progress of immune checkpoint therapy in the clinic (Review). 2019 , 41, 3-14	18
1753	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. 2018 , 6,	20
1752	Gene code : from molecular basis toward cancer immunotherapy. 2018 , 10, 1758835918815598	20
1751	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. 2018 , 995, 1-41	2
1750	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?. 2018 , 7, S275-S279	22
1749	Chimioth�rapie de premi�re ligne incluant le traitement de maintenance et les anti-angiog�niques dans les CBNPC avanc�s en lâabsence d�ddiction oncog�nique. 2018 , 10, 369-379	
1748	Traitements de deuxi�me ligne et ult�rieurs des cancers broncho-pulmonaires non ^petites cellules sans addiction oncog�nique. 2018 , 10, 385-390	

1747	Prise en charge thérapeutique des cancers bronchiques non ^petites cellules de stades avancés mutés pour l'EGFR. 2018 , 10, 425-439	0
1746	Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. 2018 , 9, 35439-35447	2
1745	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. 2018 , 7,	38
1744	Immunotherapy. 2018 ,	3
1743	The Nobel Prize for Medicine awarded for cancer therapy by inhibition of negative immune regulation. 2018 , 183, 698-700	11
1742	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. 2018 , 10, 5537-5544	1
1741	Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires. 2018 , 10, 469-480	
1740	Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. 2019 , 10, 137-143	24
1739	The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. 2018 , 7, 324-332	8
1738	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. 2018 , 125, 115-120	16
1737	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. 2018 , 11, 6189-6196	35
1736	A review of guidelines for lung cancer. 2018 , 10, S1556-S1563	41
1735	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. 2018 , 154, 1416-1423	111
1734	Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. 2018 , 9, 1500-1508	13
1733	Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. 2018 , 18, 1231-1239	10
1732	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. 2018 , 12, 2857-2873	7
1731	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. 2018 , 19, 1468-1479	237
1730	The intracellular signalosome of PD-L1 in cancer cells. 2018 , 3, 26	108

1729	[IoNECO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer]. 2018 , 35, 983-988	5
1728	Immuntherapien beim fortgeschrittenen NSCLC. 2018 , 39, 371-384	
1727	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. 2018 , 9, 1050	31
1726	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv192-iv237	897
1725	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. 2018 , 15, 116-123	31
1724	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. 2018 , 379, 2220-2229	1236
1723	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. 2018 , 379, 2040-2051	1582
1722	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). 2018 , 115, E10119-E10126	128
1721	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. 2018 , 13, 76-84	5
1720	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. 2018 , 25, 374-386	10
1719	Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. 2018 , 19, 197	8
1718	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. 2018 , 10, 1294-1299	3
1717	Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. 2018 , 553, 483-509	39
1716	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. 2018 , 10, 79	23
1715	ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). 2018 , 124, 4667-4675	7
1714	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. 2018 , 13, 1906-1918	50
1713	Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. 2018 , 2018, 3820956	14
1712	Durvalumab in NSCLC: latest evidence and clinical potential. 2018 , 10, 1758835918804151	16

1711	Predictive biomarkers for tumor immune checkpoint blockade. 2018 , 10, 4501-4507	16
1710	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. 2018 , 13, 1733-1742	79
1709	Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. 2018 , 29, 2092-2097	36
1708	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. 2018 , 32, 1541-1550	4
1707	Hyperprogressive disease: recognizing a novel pattern to improve patient management. 2018 , 15, 748-762	206
1706	Advancing therapies in metastatic castration-resistant prostate cancer. 2018 , 19, 1797-1804	13
1705	Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. 2018 , 9, 3489-3499	10
1704	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. 2018 , 9, 8706-8715	52
1703	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. 2018 , 9, 2265	77
1702	TIM-3, a promising target for cancer immunotherapy. 2018 , 11, 7005-7009	107
1701	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. 2018 , 29, 2247-2253	69
1700	TIM-3 expression in breast cancer. 2018 , 7, e1502128	34
1699	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. 2018 , 132, 125-129	14
1698	Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. 2018 , 8, 423	95
1697	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. 2018 , 67, 1853-1862	11
1696	[Molecular predictors in immune oncology]. 2018 , 39, 546-555	2
1695	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. 2018 , 12, 1753466618794133	27
1694	Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. 2018 , 16, 179	24

1693	Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality. 2018 , 9, 419-422	3
1692	Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. 2018 , 19,	39
1691	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. 2018 , 4, 1543-1552	380
1690	The nephrotoxicity of immune checkpoint inhibitor-based combinations. 2018 , 103, 274-278	2
1689	New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. 2018 , 4,	2
1688	Combinations of Bevacizumab With Cancer Immunotherapy. 2018 , 24, 193-204	89
1687	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. 2018 , 125, 86-92	31
1686	Atezolizumab Treatment of Nonsquamous NSCLC. 2018 , 379, 1188	7
1685	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. 2018 , 362, k3529	205
1684	Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung Adenocarcinoma. 2018 , 19, e879-e884	6
1683	Radiological Features of IDO1/PDL1 Lung Adenocarcinoma: A Retrospective Single-institution Study. 2018 , 38, 5295-5303	2
1682	PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. 2018 , 19, e957-e963	17
1681	Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies. 2018 , 9, 31411-31421	24
1680	sLAG-3 in non-small-cell lung cancer patients' serum. 2018 , 11, 4781-4784	12
1679	A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. 2018 , 143, 2592-2601	14
1678	Cure in metastatic breast cancer. 2018 , 11, 172-179	17
1677	Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. 2018 , 97, e11936	56
1676	Strategies for Predicting Response to Checkpoint Inhibitors. 2018 , 13, 383-395	17

1675	Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC. 2018 , 13, 1242-1244	5
1674	EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?. 2018 , 13, 1245-1247	1
1673	PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth". 2018 , 13, 1239-1241	
1672	Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. 2018 , 124, 248-254	40
1671	PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. 2018 , 29, 2085-2091	127
1670	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. 2018 , 9, 1519-1521	13
1669	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. 2018 , 10, 6636-6652	25
1668	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. 2018 , 32, 527-542	9
1667	Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. 2018 , 19, e667-e673	9
1666	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. 2018 , 8, 822-835	648
1665	The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. 2018 , 22, 467-476	18
1664	Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. 2018 , 9, 847-855	64
1663	Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. 2018 , 13, 399-407	12
1662	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. 2018 , 56, 460-472	13
1661	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30
1660	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. 2018 , 13, 1146-1155	57
1659	Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. 2018 , 13, 1324-1337	18
1658	Emerging biomarkers for immune checkpoint inhibition in lung cancer. 2018 , 52, 269-277	54

1657	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. 2018 , 10, 1758835918772810	11
1656	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 2018 , 23, 1171-1177	19
1655	Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient. 2018 , 19, e591-e596	2
1654	Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 741-744	4
1653	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. 2018 , 68, 69-79	36
1652	Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer. 2018 , 38, 3587-3592	5
1651	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. 2018 , 38, 3689-3697	23
1650	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. 2018 , 144, 1601-1611	6
1649	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. 2018 , 19, 441-449.e4	42
1648	Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. 2018 , 121, 70-75	29
1647	The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. 2018 , 198, 24-38	11
1646	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. 2018 , 19, 737-746	353
1645	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661	133
1644	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. 2018 , 13, 1156-1170	134
1643	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. 2018 , 122, 234-242	15
1642	Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. 2018 , 2018, 1027323	26
1641	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. 2018 , 23, 1358-1365	139
1640	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. 2018 , 129, 27-39	28

1639	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. 2018 , 13, e0198634	18
1638	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. 2018 , 8, 9686	0
1637	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. 2018 , 29, 1727-1740	12
1636	Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas. 2018 , 29, 550-557	30
1635	30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). 2018 , 3, e000298	7
1634	Blockade of the Checkpoint Inhibitor Pathways and Activated T-Cell Therapy in Brain Tumors. 2018 , 669-680	
1633	The changing scenario of 1 line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. 2018 , 130, 1-12	16
1632	Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. 2018 , 32, 887-891	6
1631	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. 2018 , 19, 43	8
1630	Real-World Pseudoprogression: an Uncommon Phenomenon. 2018 , 13, 880-882	9
1629	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. 2018 , 33, 94-104	6
1628	HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?. 2018 , 13, 874-876	4
1627	Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. 2018 , 69, 143-151	16
1626	Durvalumab for the treatment of non-small cell lung cancer. 2018 , 12, 627-639	16
1625	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). 2018 , 40, 173-189	22
1624	Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 2018 , 8, 278	7
1623	Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer. 2018 , 25, S94-S102	28
1622	Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. 2018 , 25, S68-S76	6

1621	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. 2018 , 81, 29-41	12
1620	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. 2018 , 10,	24
1619	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. 2018 , 13, 1248-1268	331
1618	KRAS-Mutant non-small cell lung cancer: From biology to therapy. 2018 , 124, 53-64	133
1617	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. 2018 , 10,	155
1616	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. 2018 , 140, 317-328	71
1615	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. 2018 , 24, 1441-1448	581
1614	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. 2018 , 18, 937-945	10
1613	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. 2018 , 9, 2302-2307	16
1612	Cigarette Smoke-Induced Emphysema Exhausts Early Cytotoxic CD8 T Cell Responses against Nascent Lung Cancer Cells. 2018 , 201, 1558-1569	10
1611	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. 2018 , 9, 1200-1206	22
1610	Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma. 2018 , 32, 2058738418790318	23
1609	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. 2018 , 13, 47	24
1608	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. 2018 , 10, 931-940	8
1607	Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. 2018 , 11, 3691-3696	28
1606	Immunotherapy in Glioblastoma. 2018 , 116, 518-528	23
1605	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. 2018 , 10, 1758835918786228	5
1604	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. 2018 , 11, 4051-4064	10

1603	Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. 2018 , 13, e0199575	7
1602	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 2018 , 101, 114-122	32
1601	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. 2018 , 124, 31-39	25
1600	Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. 2018 , 15, 119-124	4
1599	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. 2018 , 101, 201-209	36
1598	Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. 2018 , 10, 887-897	7
1597	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. 2018 , 8, 86	529
1596	Editorial: Controversies in the Local Management of Lung Cancer. 2018 , 8, 233	0
1595	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. 2018 , 6, 65	70
1594	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. 2018 , 13, 509-515	21
1593	Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. 2018 , 101, 20-29	23
1592	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. 2018 , 6, 46	86
1591	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. 2018 , 14, 3-17	17
1590	New options on the horizon for nononcogene addicted non-small-cell lung cancer. 2018 , 14, 19-28	1
1589	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. 2018 , 10,	37
1588	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. 2018 , 122, 160-164	5
1587	Targeting Delivery of Lidocaine and Cisplatin by Nanogel Enhances Chemotherapy and Alleviates Metastasis. 2018 , 10, 25228-25240	22
1586	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. 2018 , 62, 29-39	496

1585	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. 2018 , 14, 2415-2431	19
1584	BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?. 2018 , 13, 1055-1057	0
1583	Phenotype molding of stromal cells in the lung tumor microenvironment. 2018 , 24, 1277-1289	607
1582	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. 2018 , 7,	8
1581	Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. 2018 , 6, 42	8
1580	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. 2018 , 10, 797-805	17
1579	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. 2018 , 100, 126-134	65
1578	Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. 2018 , 101, 287-290	7
1577	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). 2018 , 6, 39	202
1576	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). 2018 , 6, 63	165
1575	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). 2018 , 6, 75	107
1574	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. 2018 ,	5
1573	Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. 2018 , 11, 112-115	2
1572	Management of adverse events related to checkpoint inhibition therapy. 2018 , 11, 132-137	17
1571	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 2018 , 14, 41-60	7
1570	Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. 2018 , 144, 1851-1859	39
1569	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). 2018 , 13, 1393-1399	118
1568	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. 2018 , 19,	12

1567	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. 2018 , 10,	20
1566	Necitumumab: a new option for first-line treatment of squamous cell lung cancer. 2018 , 14, 765-772	3
1565	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?. 2018 , 16, 24	8
1564	Toward innovative combinational immunotherapy: A systems biology perspective. 2018 , 68, 1-8	11
1563	Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. 2018 , 4,	14
1562	PD-L1 receptor expression in vulvar carcinomas is HPV-independent. 2018 , 473, 513-516	23
1561	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. 2018 , 6, 8	606
1560	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. 2018 , 18, 333	7
1559	ZNS-Befall bei Patienten mit NSCLC. 2018 , 21, 54-62	0
1558	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. 2018 , 8, 530-538	27
1557	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. 2018 , 7, R196-R211	9
1556	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. 2018 , 19, 851-864	4
1555	Regulatory mechanisms of PD-L1 expression in cancer cells. 2018 , 67, 1481-1489	46
1554	Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer. 2018 , 130, 36-43	0
1553	Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. 2018 , 9, 7672-7683	10
1552	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. 2018 , 9, 16512-16520	50
1551	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). 2018 , 6, 144	17
1550	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'. 2018 , 19, 461-463	1

1549	Treatment of advanced non-small cell lung cancer in the elderly. 2018 , 12, 783-792	4
1548	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). 2018 , 124, 117-124	19
1547	Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. 2018 , 9, 129-134	9
1546	Current and future developments of immunotherapy in lung cancer. 2018 , 11, 122-131	0
1545	Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?. 2018 , 3, e000421	8
1544	Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. 2018 , 25, S77-S85	7
1543	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. 2018 , 144, 2245-2261	16
1542	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. 2018 , 27, 637-641	8
1541	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. 2018 , 17, 129	280
1540	Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. 2018 , 25, e324-e334	38
1539	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. 2018 , 19, 46	9
1538	Sex as a predictor of response to cancer immunotherapy. 2018 , 19, e378	0
1537	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. 2018 , 9, 1614-1622	12
1536	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. 2018 , 35, 819-834	7
1535	Review of checkpoint immunotherapy for the management of non-small cell lung cancer. 2018 , 7, 63-75	36
1534	Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. 2018 , 8, 11738	16
1533	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. 2018 , 24, 5543-5551	11
1532	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. 2018 , 6, 771-781	107

1531	Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects. 2018 , 8, 277		13
1530	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. 2018 , 10, 2475-2488		11
1529	The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. 2018 , 12, 981-986		25
1528	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. 2018 , 14, 120-136		
1527	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. 2018 , 35, 132		32
1526	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018 , 392, 123-133	40	624
1525	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. 2018 , 378, 2288-2301		1695
1524	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. 2018 , 4, 1189-1197		39
1523	-Oncogenic and -Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer. 2018 , 24, 4579-4587		44
1522	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. 2018 , 29, 1701-1709		11
1521	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. 2018 , 93, 917-936		3
1520	Spotlight on atezolizumab and its potential as an oncology agent. 2018 , 18, 719-722		2
1519	Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. 2018 , 10, 681-694		25
1518	Immunotherapy combinations emerging in non-small-cell lung cancer. 2018 , 10, 627-629		
1517	Recent progress in therapeutic antibodies for cancer immunotherapy. 2018 , 44, 56-65		19
1516	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. 2018 , 23, 1052-1059		20
1515	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. 2019 , 105, 582-597		7
1514	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. 2019 , 29, 29-39		29

1513	A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. 2019 , 105, 486-495	14
1512	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. 2019 , 74, 49-60	16
1511	Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?. 2019 , 43, 43-53	1
1510	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. 2019 , 25, 957-966	28
1509	Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. 2019 , 74, 269-275	9
1508	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. 2019 , 193, 20-30	35
1507	Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. 2019 , 20, 208-214.e2	53
1506	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. 2019 , 293, 15-29	23
1505	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 2019 , 11, 873-879	10
1504	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). 2019 , 20,	55
1503	Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). 2019 , 37, 1266-1273	21
1502	Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. 2019 , 11, 521-534	12
1501	Mutationslast im Plasma als klinischer Prädiktor beim NSCLC. 2019 , 25, 540-542	
1500	Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. 2019 , 11, 2664-2668	1
1499	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. 2019 , 8, 202-207	7
1498	PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. 2019 , 10, 2022	155
1497	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. 2019 , 20, 1395-1408	149
1496	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. 2019 , 19, 495-509	250

1495	Treatment of uncommon mutations in non-small cell lung cancer: new evidence and treatment. 2019 , 8, 302-316	45
1494	Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. 2019 , 11, 993-1003	11
1493	Therapeutic outcomes in non-small cell lung cancer with mutations: a single institution, retrospective cohort study. 2019 , 8, 258-267	7
1492	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. 2019 , 15, 2371-2383	2
1491	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. 2019 , 11, 1149-1160	8
1490	Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. 2019 , 8,	46
1489	Effect and biomarker of Nivolumab for non-small-cell lung cancer. 2019 , 117, 109199	16
1488	Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies. 2019 , 20, 451-460.e5	4
1487	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. 2019 , 233, 116713	25
1486	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. 2019 , 15, 2423-2433	48
1485	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. 2019 , 6, e459-e469	104
1484	Recent advances in the vibrational spectroscopic diagnosis of non-small cell lung cancer. 2019 , 104, 102946	2
1483	PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. 2019 , 15, 1667-1678	6
1482	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. 2019 , 15, 2743-2757	5
1481	Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience. 2019 , 11, 945-952	2
1480	Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. 2019 , 125, 4019-4032	53
1479	Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. 2019 , 94, 1623-1640	481
1478	Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. 2019 , 11, 7707-7719	18

1477	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. 2019 , 8,	18
1476	Novel Delivery Systems for Checkpoint Inhibitors. 2019 , 6,	15
1475	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. 2019 , 36, 168-178.e4	124
1474	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. 2019 , 5, 1276-1282	328
1473	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. 2019 , 5, 1195-1204	224
1472	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. 2019 , 142, 35-43	13
1471	Opportunities of circulating tumor DNA in lung cancer. 2019 , 78, 31-41	12
1470	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. 2019 , 8,	17
1469	Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. 2019 , 7, 176	36
1468	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. 2019 , 12, 75	49
1467	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. 2019 ,	
1466	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. 2019 , 142, 16-25	17
1465	A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer. 2019 , 12, 4955-4973	7
1464	Possible Biomarkers for Cancer Immunotherapy. 2019 , 11,	22
1463	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. 2019 , 135, 188-195	99
1462	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. 2019 , 2, e196879	97
1461	First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis. 2019 , 125, 3526-3534	46
1460	Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. 2019 , 33, e22964	66

1459	Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging. 2019 , 16, 3469-3476	13
1458	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. 2019 , 65-84	
1457	Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer. 2019 , 26, e300-e308	3
1456	Practical Application of Real-World Evidence in Developing Cancer Therapies. 2019 , 3, 1-2	3
1455	The biological functions and clinical applications of exosomes in lung cancer. 2019 , 76, 4613-4633	58
1454	BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. 2019 , 9, 60	5
1453	Clinical utility of ramucirumab in non-small-cell lung cancer. 2019 , 13, 133-137	3
1452	Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs. 2019 , 11, 1083-1086	5
1451	Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. 2019 , 110, 2711-2721	17
1450	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer. 2019 , 10, 47-56	9
1449	Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. 2019 , 9, 478	8
1448	Determinants of immunological evasion and immunecheckpoint inhibition response in non-small cell lung cancer: the genetic front. 2019 , 38, 5921-5932	14
1447	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. 2019 , 12, 67	26
1446	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. 2019 , 134, 210-217	8
1445	Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.. 2019 , 9, 17921-17932	0
1444	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. 2019 , 10, 673	35
1443	Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. 2019 , 20, 391-396	23
1442	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). 2019 , 105, 3-14	6

1441	Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. 2019 , 39, 3917-3921	26
1440	Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. 2019 , 74, 105707	8
1439	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. 2019 , 14, 1619-1627	6
1438	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. 2019 , 11,	4
1437	Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. 2019 , 8, 4699-4708	30
1436	Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action. 2019 , 10, 1187-1192	18
1435	Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody. 2019 , 9, 15205	13
1434	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. 2019 , 19, 1247-1263	19
1433	Immunotherapy of brain metastases: breaking a "dogma". 2019 , 38, 419	31
1432	Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 T Cells in Non-Small Cell Lung Cancer. 2019 , 20,	8
1431	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. 2019 , 138, 58-64	2
1430	Immuntherapie des metastasierten nichtkleinzelligen Lungenkarzinoms. 2019 , 16, 353-365	
1429	Systemtherapie des metastasierten NSCLC. 2019 , 22, 24-29	
1428	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. 2019 , 4, e000531	34
1427	Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. 2019 , 5, FSO421	19
1426	Letter to the Editor about Sorich et'al. 2019 , 14, e209	4
1425	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. 2019 , 9, 972	11
1424	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. 2019 , 42, 101295	8

1423	Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. 2019 , 9, 944	10
1422	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. 2019 , 11, 3794-3807	2
1421	The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials. 2019 , 77, 105975	4
1420	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. 2019 , 11,	54
1419	Advances in Engineering Cells for Cancer Immunotherapy. 2019 , 9, 7889-7905	29
1418	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. 2019 , 11,	17
1417	Medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms. 2019 , 16, 397-409	1
1416	Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). 2019 , 47, 4194-4201	5
1415	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. 2019 , 10, 1260	13
1414	Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxitol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy. 2019 , 15, e1904378	22
1413	The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. 2019 , 11, 1481-1490	8
1412	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. 2019 , 10, 1453	13
1411	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. 2019 , 15, 3633-3646	4
1410	Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers. 2019 , 31, e1904997	139
1409	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. 2019 , 8,	22
1408	Quantifying treatment effects using the personalized chance of longer survival. 2019 , 38, 5317-5331	0
1407	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. 2019 , 14, 2084-2096	27
1406	Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer. 2019 , 10, 2179-2182	2

1405	KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. 2019 , 11, S1963-S1965	2
1404	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. 2019 , 11, 3909-3919	2
1403	Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. 2019 , 11, 3757-3768	19
1402	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. 2019 , 14, 707-717	11
1401	An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. 2019 , 158, 136-149	8
1400	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. 2019 , 8, S139-S146	7
1399	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. 2019 , 26, 1073274819870549	10
1398	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. 2019 , 10, 2006-2012	29
1397	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. 2019 , 110, 3244-3254	20
1396	Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature. 2019 , 13, 316	12
1395	Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan. 2019 , 24, 1549-1557	3
1394	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. 2019 , 25, 6061-6072	33
1393	Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. 2019 , 136, 45-51	47
1392	Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report. 2019 , 12, 564-567	1
1391	Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. 2019 , 68, 1537-1545	6
1390	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. 2019 , 12, 92	256
1389	Immunotherapy in inoperable stage III non-small cell lung cancer: a review. 2019 , 8, 212578	3
1388	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. 2019 , 8, 19	23

1387	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. 2019 , 11,	19
1386	The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. 2019 , 9, 866	7
1385	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. 2019 , 2019, 6832909	15
1384	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. 2019 , 11, 1758835919870360	26
1383	Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD. 2019 , 14, 1867-1877	7
1382	Resistance to Targeted Therapies in Lymphomas. 2019 ,	
1381	Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer. 2019 , 2, e1911895	26
1380	PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. 2019 , 136, 136-144	33
1379	Clinical and immune profiling for cancer of unknown primary site. 2019 , 7, 251	14
1378	A radiomics model for determining the invasiveness of solitary pulmonary nodules that manifest as part-solid nodules. 2019 , 74, 933-943	21
1377	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. 2019 , 18, 139	78
1376	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. 2019 , 137, 108-112	9
1375	Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. 2019 , 11, 8201-8207	20
1374	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. 2019 , 14, 1935-1947	33
1373	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States. 2019 , 2, e1911952	29
1372	Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain. 2019 , 381, 1268-1277	7
1371	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. 2019 , 20,	28
1370	Measuring tumor mutation burden in cell-free DNA: advantages and limits. 2019 , 8, 553-555	1

1369	Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. 2019 , 9, 819	8
1368	Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis. 2019 , 8, e1665974	7
1367	Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. 2019 , 41, 1010428319873749	2
1366	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. 2019 , 8, 450-460	8
1365	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. 2019 , 11,	32
1364	A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. 2019 , 137, 136-143	5
1363	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. 2019 , 8,	10
1362	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. 2019 , 36, 444-457.e7	69
1361	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2019 , 121, 123-129	63
1360	Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. 2019 , 14, 1440-1446	53
1359	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). 2019 , 14, 1839-1846	31
1358	Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. 2019 , 137, 56-63	26
1357	Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. 2019 , 35, 150932	18
1356	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. 2019 , 84, 1257-1267	33
1355	Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. 2019 , 31, 24-28	13
1354	Making cold malignant pleural effusions hot: driving novel immunotherapies. 2019 , 8, e1554969	26
1353	First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis. 2019 , 11, 311-320	5
1352	EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. 2019 , 20, e238-e241	13

1351	Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. 2019 , 67, 905-912	61
1350	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. 2019 , 11, 429-441	29
1349	PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. 2019 , 135, 128-134	48
1348	Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. 2019 , 130, 10-17	66
1347	Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis. 2019 , 11, 189-199	38
1346	Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?. 2019 , 11, 161-166	2
1345	Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. 2019 , 11, 149-153	5
1344	Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression. 2019 , 10, 211-222	16
1343	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. 2019 , 5, 393-401	178
1342	ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study. 2019 , 145, 765-774	17
1341	Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. 2019 , 129, 75-79	64
1340	GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. 2019 , 145, 1111-1124	26
1339	Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!. 2019 , 30, 165-167	2
1338	Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. 2019 , 11, 407-428	33
1337	The RANK-RANKL axis: an opportunity for drug repurposing in cancer?. 2019 , 21, 977-991	16
1336	Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. 2019 , 55, 124-125	2
1335	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. 2019 , 133, 181-193	30
1334	Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC. 2019 , 22, 68-73	

1333	Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis. 2019 , 11, 3957-3969	5
1332	Combining immunotherapies to treat non-small cell lung cancer. 2019 , 13, 621-634	0
1331	Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. 2019 , 38, 253	40
1330	Precision Medicine in Cancer Therapy. 2019 ,	1
1329	Targeted Therapies in Non-small-Cell Lung Cancer. 2019 , 178, 3-43	11
1328	Immunohistochemistry-Enabled Precision Medicine. 2019 , 178, 111-135	4
1327	PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC. 2019 , 24, 1198-1203	16
1326	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. 2019 , 9, 1208-1227	45
1325	Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. 2019 , 11, 769-782	6
1324	China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. 2019 , 39, 36	37
1323	Prospects for a personalized peptide vaccine against lung cancer. 2019 , 18, 703-709	5
1322	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. 2019 , 30, 1448-1459	89
1321	Checkpoint Inhibitors. 2019 , 116, 119-126	42
1320	Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. 2019 , 4, e000498	27
1319	Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. 2019 , 2168479019855994	
1318	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. 2019 , 134, 245-253	23
1317	A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials. 2019 , 144, 235-237	4
1316	Assessing the interactions between radiotherapy and antitumour immunity. 2019 , 16, 729-745	95

1315	Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). 2019 , 12, 4235-4244	30
1314	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. 2019 , 84, 227-240	34
1313	Molecular profile of non-small cell lung cancer in northeastern Brazil. 2019 , 45, e20180181	7
1312	Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. 2019 , 11, e10293	80
1311	Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. 2019 , 116, 86-97	14
1310	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. 2019 , 14, 1046-1060	28
1309	Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1 triple negative breast cancer cells. 2019 , 8, e1624128	19
1308	Application of PD-1 Blockade in Cancer Immunotherapy. 2019 , 17, 661-674	184
1307	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. 2019 , 66, 1-8	14
1306	MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. 2019 , 17, 5193-5200	13
1305	Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma. 2019 , 17, 5487-5498	7
1304	The miRNA hsa-miR-6515-3p potentially contributes to lncRNA H19-mediated-lung cancer metastasis. 2019 , 120, 17413-17421	11
1303	Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN γ signaling in non-small cell lung cancer. 2019 , 14, e0216864	6
1302	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. 2019 , 11,	55
1301	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. 2019 , 8,	28
1300	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. 2019 , 37, 2511-2513	15
1299	Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. 2019 , 10, 3294-3301	7
1298	Platycodin D triggers the extracellular release of prograded death Ligand-1 in lung cancer cells. 2019 , 131, 110537	20

1297	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. 2019 , 134, 259-267	19
1296	Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. 2019 , 8, 4023-4031	25
1295	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. 2019 , 14, e0217991	5
1294	Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab. 2019 , 110, 410-411	
1293	Salvage treatment with anlotinib for advanced non-small cell lung cancer. 2019 , 10, 1590-1596	20
1292	Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. 2019 , 11, 287-291	0
1291	High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling. 2019 , 25, 5503-5512	69
1290	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. 2019 , 19, 558	63
1289	A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. 2019 , 84, 567-578	1
1288	EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. 2019 , 30, 1190-1192	3
1287	TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas. 2019 , 11, 4743-4756	6
1286	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. 2019 , 38, 255	296
1285	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. 2019 , 25, 5061-5068	36
1284	Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. 2019 , 14, e0217276	16
1283	Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. 2019 , 11,	40
1282	The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. 2019 , 92, 20181031	17
1281	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. 2019 , 145, 104258	61
1280	Nivolumab plus ipilimumab in non-small-cell lung cancer. 2019 , 15, 2287-2302	23

1279	Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. 2019 , 20,	20
1278	Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. 2019 , 39, 3-10	81
1277	Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. 2019 , 39, e187-e197	17
1276	Immunotherapy in Older Adults: A Checkpoint to Palliation?. 2019 , 39, e110-e120	8
1275	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. 2019 , 20, 924-937	562
1274	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. 2019 , 54, 538-545	22
1273	Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. 2019 , 58, 953-961	24
1272	Comment on 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'-No support for de-escalation of immunotherapy. 2019 , 115, 24-26	
1271	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. 2019 , 16, 563-580	584
1270	Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer. 2019 , 39, 2561-2567	2
1269	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. 2019 , 25, 4808-4819	42
1268	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. 2019 , 42, 1230-1239	2
1267	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. 2019 , 25, 5015-5026	67
1266	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. 2019 , 49, 762-765	30
1265	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. 2019 , 38, 193	42
1264	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. 2019 , 2019, 9056417	28
1263	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248
1262	Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy. 2019 , 20, 287-296.e4	21

1261	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. 2019 , 21, 603-611	9
1260	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients. 2019 , 10, 1303-1309	6
1259	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. 2019 , 11, S347-S351	5
1258	Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. 2019 , 5, 1043-1047	147
1257	A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. 2019 , 84, 351-358	5
1256	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. 2019 , 20,	20
1255	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. 2019 , 9, 264	59
1254	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. 2019 , 20,	41
1253	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. 2019 , 76, 22-32	131
1252	Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. 2019 , 10, 2025	231
1251	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. 2019 , 2, e193433	8
1250	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. 2019 , 24, 731-770	63
1249	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. 2019 , 5, 1008-1019	288
1248	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. 2019 , 67, 1012-1019	2
1247	The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations. 2019 , 10, 610-614	3
1246	Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. 2019 , 26,	14
1245	Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. 2019 , 14, e0215135	6
1244	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. 2019 , 20,	39

1243	The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?. 2019 , 31, 432-443	26
1242	Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. 2019 , 37, 1863-1867	51
1241	Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy. 2019 , 39, 1997-2005	2
1240	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. 2019 , 143, 63-144	26
1239	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. 2019 , 11, 1758835919839928	28
1238	Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. 2019 , 19, 392	3
1237	Emerging therapies for non-small cell lung cancer. 2019 , 12, 45	69
1236	KEYNOTE-024: goodbye to chemotherapy?. 2019 , 11, S428-S432	2
1235	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. 2019 , 36, 49	11
1234	Immunotherapy causing pneumonitis in a patient with non-small cell lung cancer (NSCLC). 2019 , 12,	2
1233	Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. 2019 , 9, 156	67
1232	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. 2019 , 145, 1341-1349	13
1231	Elevated Heme Synthesis and Uptake Underpin Intensified Oxidative Metabolism and Tumorigenic Functions in Non-Small Cell Lung Cancer Cells. 2019 , 79, 2511-2525	28
1230	Antigen Targets for the Development of Immunotherapies in Leukemia. 2019 , 20,	6
1229	Hypoxia-inducible factor-1 α and nuclear factor- κ B play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. 2019 , 110, 1665-1675	28
1228	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. 2019 , 21, 1464-1471	1
1227	Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. 2019 , 25, 4881-4887	5
1226	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). 2019 , 14, 1095-1101	85

1225	Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma. 2019 , 14, 857-866	18
1224	Adjuvant and Neoadjuvant Therapy in Non-Small-Cell Lung Cancer. 2019 , 35-55	
1223	Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. 2019 , 9, 47	32
1222	Management of Locally Advanced Lung Cancer. 2019 , 57-86	1
1221	Lung Adenocarcinoma. 2019 , 103-114	2
1220	Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. 2019 , 115-131	
1219	Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC). 2019 , 22, 625-637	15
1218	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. 2019 , 24, 461-467	5
1217	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. 2019 , 25, 4592-4602	241
1216	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. 2019 , 26, 1925-1933	17
1215	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. 2019 , 36, 33	29
1214	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. 2019 , 33, 159-171	33
1213	Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. 2019 , 1871, 323-330	9
1212	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. 2019 , 24, S31-S41	117
1211	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. 2019 , 13, 438-450	17
1210	Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. 2019 , 55, 124-125	
1209	Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. 2019 , 58, 137-156.e1	25
1208	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. 2019 , 30, 884-896	51

1207	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1-Line Treatment for Non-Small-Cell Lung Cancer. 2019 , 13, 1-6	22
1206	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. 2019 , 19, 547-559	11
1205	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. 2019 , 30, 1134-1142	59
1204	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. 2019 , 10, 1125	73
1203	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. 2019 , 41, 711-716	70
1202	From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. 2019 , 2019, 3267409	9
1201	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 2019 , 9, 179	23
1200	Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. 2019 , 26, e81-e93	20
1199	Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. 2019 , 17, 2946-2952	50
1198	Efficacy and safety of immune checkpoint blockade for brain metastases. 2019 , 8, CNS33	9
1197	Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. 2019 , 9, 4278	19
1196	Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials. 2019 , 11, 1623-1629	11
1195	Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. 2019 , 12, 1521-1538	3
1194	The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses. 2019 , 11,	26
1193	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. 2019 , 13, 435-447	5
1192	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. 2019 , 11, 515-529	12
1191	Recent clinical trials of immunotherapy in non-small-cell lung cancer. 2019 , 11, 461-466	3
1190	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. 2019 , 68, 917-926	39

1189	Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?. 2019 , 37, 529-536	7
1188	Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. 2019 , 39, 1749-1760	16
1187	Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer. 2019 , 39, 1987-1996	7
1186	Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis. 2019 , 8, 2664-2674	15
1185	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. 2019 , 37, 992-1000	274
1184	Combined Inhibition of TGF- β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. 2019 , 8,	51
1183	Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales. 2019 , 456, 23-28	16
1182	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. 2019 , 138, 87-103	8
1181	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. 2019 , 132, 72-78	34
1180	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. 2019 , 24, 1270-1284	14
1179	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials. 2019 , 10, 1176-1181	6
1178	Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. 2019 , 14, e0215292	4
1177	Telomerase-Targeted Cancer Immunotherapy. 2019 , 20,	42
1176	Are we ready to describe response or progression to immunotherapy in lung cancer?. 2019 , 138, 112-119	5
1175	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. 2019 , 7, 387-401	398
1174	The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma. 2019 , 19, 289	13
1173	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. 2019 , 14, 1244-1254	106
1172	Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab. 2019 , 37, 1257-1265	5

1171	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. 2019 , 10, 491	11
1170	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). 2019 , 23, 311-331	61
1169	Immunological Agents Used in Cancer Treatment. 2019 , 51, 90-94	21
1168	Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells. 2019 , 11, 7996-8011	5
1167	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. 2019 , 37, 52-60	151
1166	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. 2019 , 19, 332-344	13
1165	Early Phase I Study of a Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. 2019 , 60, 1213-1220	61
1164	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. 2019 , 8, 1521-1529	41
1163	Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice. 2019 , 15, 2915-2931	19
1162	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. 2019 , 37, 531-537	1
1161	Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. 2019 , 30, 830-838	45
1160	Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy. 2019 , 9, e25-e26	3
1159	Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. 2019 , 10, 561-572	7
1158	Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis. 2019 , 13, 523-538	8
1157	Immunotherapy. 2019 , 173-189	
1156	Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. 2019 , 20, 178-185.e2	23
1155	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. 2019 , 68, 341-352	54
1154	Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis. 2019 , 10, 607-623	15

1153	Novel insights into the systemic treatment of lung cancer malignant pleural effusion. 2019 , 13, 131-138	6
1152	Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. 2019 , 11, 467-472	17
1151	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. 2019 , 11, S89-S101	43
1150	Nivolumab-refractory patients with advanced non-small-cell lung cancer. 2019 , 130, 128-134	12
1149	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. 2019 , 25, 3220-3228	99
1148	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. 2019 , 21, 1270-1279	21
1147	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. 2019 , 39, 341-353	13
1146	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. 2019 , 29, 396-416	37
1145	Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. 2019 , 10, 209-215	28
1144	Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. 2019 , 151-171	
1143	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. 2019 , 11, S25-S36	31
1142	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. 2019 , 20, 21	16
1141	Curative effect assessment of immunotherapy for non-small cell lung cancer: The "blind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST). 2019 , 10, 587-592	8
1140	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. 2019 , 10, 108	68
1139	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. 2019 , 474, 421-432	28
1138	Base excision repair regulates PD-L1 expression in cancer cells. 2019 , 38, 4452-4466	42
1137	Immunotherapy in extensive small cell lung cancer. 2019 , 8, 5	18
1136	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. 2019 , 15, 1363-1383	8

1135	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. 2019 , 11,	35
1134	Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies.. 2019 , 8, E18-E23	
1133	Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?. 2019 , 7, S282	3
1132	Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock. 2019 , 8, S360-S363	2
1131	Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC. 2019 , 8, 1045-1050	4
1130	Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. 2019 , 8, S323-S326	5
1129	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. 2019 , 2019, 6051870	5
1128	Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities-a commentary of the 3-year follow-up of the KEYNOTE-001 trial.. 2019 , 8, S598-S602	2
1127	Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. 2019 , 8, 1078-1085	21
1126	Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", Mèdica Sur Hospital. 2019 , 23, 239-246	
1125	Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis. 2019 , 11, 10767-10775	2
1124	Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials.. 2019 , 3, 1-10	22
1123	Traitements de premièrre ligne dans les CBNPC avancè, en lâbsence dâddiction oncoghique (incluant le traitement de maintenance et les anti-angioghiques). 2019 , 11, 342-354	
1122	Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. 2019 , 8, 920-928	1
1121	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. 2019 , 28,	22
1120	PD-L1 and tumor-associated macrophages in de novo DLBCL. 2019 , 3, 531-540	37
1119	Latest Immunotherapy Methods in Non-small Cell Lung Cancer Treatment. 2019 , 65, 444-450	
1118	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. 2019 , 8, 847-853	24

1117	Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. 2019 , 24, e1165-e1171	23
1116	Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. 2019 , 11, 4982-4991	17
1115	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. 2019 , 55,	
1114	Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?. 2019 , 8, 710-714	3
1113	Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer. 2019 , 11, 4092-4095	3
1112	Immune checkpoint inhibitors win the 2018 Nobel Prize. 2019 , 42, 299-306	24
1111	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. 2019 , 8, 723-727	2
1110	Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR β Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. 2019 , 10, 2213	2
1109	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. 2019 , 11,	50
1108	Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. 2019 , 14, 759-768	8
1107	Preface: More than two decades of modern tumor immunology. 2019 , 629, xxi-xl	1
1106	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NF κ B ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). 2019 , 20, 753	10
1105	Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation. 2019 , 3,	3
1104	Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer. 2019 , 1, 182-192	18
1103	Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?. 2019 , 1, 193-195	0
1102	Cancer du poumon. 2019 , 11, S29-S35	
1101	Biomarqueurs prédictifs et inhibiteurs des points de contrôle immunitaires au cours des cancers bronchopulmonaires non à petites cellules. 2019 , 11, S468-S475	
1100	Immunothérapie pratique, pratique de l'immunothérapie: de la prise en charge initiale au suivi. 2019 , 11, S502-S507	

1099	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis. 2019 , 98, e18310	
1098	Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma. 2019 , 30, 873-878	3
1097	The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials. 2019 , 11, 4453-4463	3
1096	Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies. 2019 , 9, 1432	10
1095	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. 2019 , 7, 316	56
1094	Durvalumab for the treatment of non-small cell lung cancer. 2019 , 19, 1009-1016	13
1093	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. 2019 , 79, 1937-1945	4
1092	Tumour pseudoprogression during nivolumab immunotherapy for lung cancer. 2019 , 61, 498-505	1
1091	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. 2019 , 11, 1758835919885540	12
1090	Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. 2019 , 46, 380-384	14
1089	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. 2019 , 20, 263	2
1088	Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?. 2019 , 8, 715-722	5
1087	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. 2019 , 2019, 7652014	21
1086	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. 2019 , 26, 96	19
1085	18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. 2019 , 40, 802-807	43
1084	Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis. 2019 , 42, 711-716	2
1083	The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis. 2019 , 98, e16439	1
1082	Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience. 2019 , 98, e17348	15

1081	Biomarker for personalized immunotherapy. 2019 , 8, S308-S317	5
1080	Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study. 2019 , 9, 1394	23
1079	NSCLC: Real-Life-Studie VARGADO adressiert Fragen zur Therapiesequenz. 2019 , 42, 696-697	
1078	Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer. 2019 , 30, 1067-1070	2
1077	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. 2019 , 32, 500-510	37
1076	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. 2019 , 28,	48
1075	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. 2019 , 18, 1534735419890020	20
1074	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. 2019 , 4, 61	223
1073	Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials. 2019 , 98, e15731	13
1072	Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis. 2019 , 24, 75-83	19
1071	How Ginsenosides Trigger Apoptosis in Human Lung Adenocarcinoma Cells. 2019 , 47, 1737-1754	13
1070	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). 2019 , 27, 699-714	23
1069	Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience. 2019 , 33, F13-F19	35
1068	Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. 2019 , 39, 6851-6857	14
1067	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. 2019 , 11,	39
1066	Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy. 2019 , 58, vii1-vii6	1
1065	Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. 2019 , 58, 3283-3287	8
1064	[The revolution of immuno-oncology therapy [review of immune checkpoint inhibitors efficacy]. 2019 , 35, 937-945	2

1063	Immunotherapy for non-small cell lung cancer. 2019 , 32, 37-42	4
1062	Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer. 2019 , 12, 11541-11547	5
1061	Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.. 2019 , 3, 1-10	5
1060	Predictive potential and need for standardization of PD-L1 immunohistochemistry. 2019 , 474, 475-484	17
1059	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. 2019 , 24, 41-45	5
1058	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. 2019 , 17, 97-108	10
1057	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. 2019 , 5, 74-82	326
1056	The Current Status of Immunotherapy in Thoracic Malignancies. 2019 , 45-75	
1055	Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. 2019 , 195, 334-344	15
1054	Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. 2019 , 130, 59-66	46
1053	The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. 2019 , 128, 113-119	8
1052	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. 2019 , 5, 529-536	109
1051	Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. 2019 , 107, 124-132	58
1050	Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. 2019 , 443, 189-202	9
1049	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. 2019 , 1871, 199-224	32
1048	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. 2019 , 128, 105-112	77
1047	Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice. 2019 , 31, 90-94	10
1046	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. 2019 , 30, 171-210	121

1045	Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. 2019 , 33, 213-220	14
1044	Product review: avelumab, an anti-PD-L1 antibody. 2019 , 15, 891-908	26
1043	PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. 2019 , 120, 3-5	48
1042	Immuno-Oncology in Lung Cancer: A Focus on Anti-PD-1 and Anti-CTLA-4 Therapy in NSCLC. 2019 , 487-497	1
1041	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). 2019 , 21, 3-17	51
1040	Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. 2019 , 14, 45-53	27
1039	The clinical features of older patients with lung cancer in comparison with their younger counterparts. 2019 , 57, 40-48	1
1038	Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. 2019 , 442, 279-286	15
1037	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. 2019 , 14, 25-36	49
1036	Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. 2019 , 144, 2854-2866	6
1035	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. 2019 , 106, 1-11	16
1034	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. 2019 , 25, 2691-2698	50
1033	Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma. 2019 , 29, 2388-2398	4
1032	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. 2019 , 20, e338-e345	7
1031	Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report. 2019 , 10, 369-372	10
1030	Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. 2019 , 128, 26-32	19
1029	Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. 2019 , 19, 225-232	16
1028	Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. 2019 , 14, 49-50	9

1027	Radiotherapy and immunotherapy: a synergistic effect in cancer care. 2019 , 210, 47-53	25
1026	Selective outcome reporting is present in randomized controlled trials in lung cancer immunotherapies. 2019 , 106, 145-146	4
1025	PD-1 Blockade in Early-Stage Lung Cancer. 2019 , 70, 425-435	15
1024	Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. 2019 , 32, 511-523	18
1023	Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients. 2019 , 96, 125-131	14
1022	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. 2019 , 120, 57-62	40
1021	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. 2019 , 335-344	1
1020	The lung microenvironment: an important regulator of tumour growth and metastasis. 2019 , 19, 9-31	347
1019	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. 2019 , 5, 358-365	28
1018	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. 2019 , 125, 1038-1049	39
1017	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. 2019 , 106, 144-159	108
1016	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. 2019 , 196, 105-116	56
1015	Implementing value assessment in oncology practice: A single-center experience. 2019 , 25, 947-953	2
1014	Metal Drugs and the Anticancer Immune Response. 2019 , 119, 1519-1624	146
1013	Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. 2019 , 110, 52-60	19
1012	Treatment of older patients with advanced non-small cell lung cancer: A challenge. 2019 , 10, 528-533	8
1011	Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. 2019 , 20, 201-207	81
1010	Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo. 2019 , 187, 1328-1343	5

1009	Multidisciplinary treatment of lung cancer in older patients: A review. 2019 , 10, 405-410	11
1008	FcR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model. 2019 , 144, 345-354	9
1007	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. 2019 , 194, 84-106	154
1006	Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. 2019 , 18, 147-156	11
1005	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. 2020 , 25, 64-77	22
1004	Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result. 2020 , 27, 171-179	34
1003	Therapeutic Antibodies and Immunologic Conjugates. 2020 , 486-499.e8	1
1002	Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors. 2020 , 28, 1-9	9
1001	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 2020 , 43, 337-345	17
1000	Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. 2020 , 61, 167-179	94
999	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. 2020 , 25, 818-830	39
998	Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. 2020 , 146, 3124-3133	23
997	The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. 2020 , 470, 95-105	93
996	Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. 2020 , 15, 138-143	18
995	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. 2020 , 22, 759-771	10
994	To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. 2020 , 75, 434-441	1
993	Behavioral, psychological, and supportive care interventions in geriatric oncology: The Cancer and Aging Research Group infrastructure core. 2020 , 11, 347-349	4
992	A multistate model for early decision-making in oncology. 2020 , 62, 550-567	4

991	Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. 2020 , 26, 564-571	10
990	Cancer of the Lung: Non-small Cell Lung Cancer and Small Cell Lung Cancer. 2020 , 1108-1158.e16	5
989	The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives. 2020 , 15, 11-19	12
988	Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. 2020 , 25, 67-73	3
987	Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. 2019 , 1-8	38
986	Current Development of Monoclonal Antibodies in Cancer Therapy. 2020 , 214, 1-70	9
985	The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. 2020 , 235, 4913-4927	26
984	Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody. 2020 , 11, 15-18	14
983	Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. 2020 , 59, 569-572	4
982	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). 2020 , 126, 260-270	89
981	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or . 2020 , 146, 441-448	7
980	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. 2020 , 11, 41-50	1
979	Atlas of Response to Immunotherapy. 2020 ,	
978	Immune checkpoint inhibitors: a promising anticancer therapy. 2020 , 25, 223-229	51
977	Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. 2020 , 159, 1598-1610.e3	9
976	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. 2020 , 139, 1-8	51
975	Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. 2020 , 25, 105-111	15
974	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. 2020 , 40, 427-433	7

973	Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers. 2020 , 34, 389-392	2
972	Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. 2019 , 12,	20
971	Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. 2020 , 69, 399-405	19
970	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. 2020 , 43, 10-15	2
969	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. 2019 , 9,	26
968	In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer. 2020 , 80, 241-262	5
967	Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. 2020 , 31, 50-60	58
966	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. 2020 , 473, 148-155	16
965	The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. 2020 , 69, 343-354	45
964	Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer. 2020 , 21, e49-e53	1
963	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. 2020 , 146, 102858	28
962	RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. 2020 , 146, 102859	7
961	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. 2020 , 15, 556-567	27
960	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. 2020 , 15, 499-519	99
959	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. 2020 , 140, 59-64	22
958	Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report. 2020 , 29, 100976	2
957	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. 2020 , 65, 51-64	35
956	Bone Metastasis: Current State of Play. 2020 , 13, 308-320	17

955	Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. 2020 , 6, 512-518	85
954	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. 2020 , 6, 375-384	110
953	Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. 2020 , 25, 165-174	14
952	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. 2020 , 121, 109625	50
951	Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer. 2020 , 21, e151-e163	4
950	Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report. 2020 , 21, e45-e48	4
949	Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?. 2020 , 15, 35-43	21
948	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. 2020 , 65, 114-122	21
947	Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis. 2020 , 21, 106-113.e5	9
946	PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers. 2020 , 28, 437-443	1
945	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. 2020 , 85, 449-459	1
944	Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. 2020 , 145, 102836	4
943	Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?. 2020 , 125, 1-11	21
942	PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups. 2020 , 44, 174-181	27
941	CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer. 2020 , 33, 893-904	6
940	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations. 2020 , 14, 125-136	30
939	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). 2020 , 11, 353-361	17
938	Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non-Small Cell Lung Adenocarcinomas. 2020 , 28, 23-29	5

937	Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review. 2020 , 76, 793-802	24
936	Radiomics of F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. 2020 , 47, 1168-1182	58
935	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. 2020 , 43, 1-7	36
934	Biomarkers that may predict response to immunotherapy in ovarian malignancies. 2020 , 32, 84-90	5
933	The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. 2020 , 146, 777-785	17
932	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. 2020 , 73, 423-430	7
931	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. 2020 , 122, 340-347	15
930	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. 2020 , 26, 787-792	20
929	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. 2020 , 25, e398-e404	9
928	The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis. 2020 , 22, 1146-1154	6
927	Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. 2020 , 85, 121-131	25
926	Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma. 2020 , 27, 2102-2109	10
925	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. 2020 , 21, 255-263.e4	10
924	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. 2020 , 59, 249-256	15
923	Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. 2020 , 38, 211-218	13
922	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. 2020 , 26, 1846-1855	35
921	Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. 2020 , 11, 120-129	10
920	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. 2020 , 21, 44-59	422

919	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. 2020 , 21, 134-144	47
918	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). 2020 , 38, 793-803	12
917	Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data. 2020 , 43, 193-202	9
916	CD4 T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. 2020 , 8, 334-344	68
915	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. 2019 , 12,	19
914	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. 2020 , 11, 741-749	8
913	Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer. 2020 , 92, e12980	9
912	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. 2020 , 21,	21
911	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade.. 2020 , 4, 1196-1206	4
910	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. 2020 , 12, 1313-1324	3
909	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial. 2020 , 3, e2013770	15
908	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. 2020 , 31, 1746-1754	58
907	[Management of immune checkpoint inhibitors-induced liver toxicity in cancer]. 2020 , 107, 1056-1068	
906	The potential of F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer. 2020 , 150, 44-52	1
905	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. 2020 , 10, 17495	6
904	Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. 2020 , 11, 3501-3509	3
903	Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA. 2020 , 98, 817-826	3
902	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. 2020 , 12,	4

901	Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. 2020 , 160, 105194	5
900	The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients. 2020 , 13, 100865	5
899	First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. 2020 , 80, 1783-1797	5
898	Non-invasive decision support for NSCLC treatment using PET/CT radiomics. 2020 , 11, 5228	53
897	TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. 2020 , 10, 17284	8
896	Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. 2020 , 133, 2466-2475	0
895	Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient. 2020 , 11, 3605-3608	2
894	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. 2020 , 14, 1383-1392	6
893	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. 2020 , 130, 110621	3
892	The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis. 2020 , 99, e22555	2
891	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. 2020 , 133, 2444-2455	3
890	Molecular mechanisms of breast cancer chemoresistance by immune checkpoints. 2020 , 263, 118604	3
889	Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. 2020 , 10, 549198	1
888	[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]. 2020 , 107, 779-791	0
887	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis. 2020 , 99, e22567	1
886	KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). 2020 , 11, 3425-3435	5
885	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. 2020 , 10, 572853	8
884	Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis. 2020 , 10, 558454	8

883	Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study. 2020 , 89, 107033	3
882	The Resistance Mechanisms of Lung Cancer Immunotherapy. 2020 , 10, 568059	14
881	An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort. 2020 , 31, 1561-1568	8
880	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. 2020 , 140, 28-36	6
879	The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients. 2020 , 149, 68-77	4
878	Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. 2020 , 9, 8406-8411	11
877	Traitements systmiques de premièe ligne dans les CBNPC avancs en lâabsence dâaddiction oncogñique. 2020 , 12, 2S173-2S184	
876	Les CBNPC de stades avancs hors addiction oncogñique : les traitements systmiques de deuxièe ligne: Advanced stage NSCLC excluding oncogenic addiction: Second-line systemic treatments. 2020 , 12, 2S185-2S194	
875	Traitement des cancers bronchiques non ^petites cellules de stades avancs muts EGFR : quels inhibiteurs ? Quelles squences thfapeutiques ?. 2020 , 12, 2S195-2S211	1
874	Prise en charge du cancer bronchique non ^petites cellules chez les sujets ñs. 2020 , 12, 2S281-2S290	
873	Recent advances in targeted nanomedicine as promising antitumor therapeutics. 2020 , 25, 2227-2244	30
872	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. 2020 , 109, 104977	3
871	CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38 β /MYC/PD-L1 signaling in non-small cell lung cancer. 2020 , 13, 99	21
870	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.. 2020 , 4, 829-840	5
869	Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. 2020 , 11, 2465-2472	3
868	Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report. 2020 , 11, 2717-2722	6
867	Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. 2020 , 11, 1479	15
866	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. 2020 , 129, 110504	9

865	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. 2020 , 147, 137-142	13
864	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. 2020 , 12, 1758835920937902	13
863	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. 2020 , 65, 21-28	2
862	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. 2020 , 12, 1758835920936882	7
861	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. 2020 , 9, 617-628	3
860	Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer. 2020 , 21, e250-e254	1
859	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies. 2020 , 9, 906-916	2
858	Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma. 2020 , 23, 101386	3
857	A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma. 2020 , 9, 833-836	
856	Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review. 2020 , 9, 1774314	16
855	Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis. 2020 , 2020, 5024942	1
854	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. 2020 , 5, 109-116	6
853	Langzeitdaten zur Therapie mit Nivolumab. 2020 , 23, 30-31	1
852	[Predictable toxicities with futures immunotherapies or combinations]. 2020 , 107, 1069-1078	1
851	Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. 2020 , 150, 178-185	6
850	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. 2020 , 8,	6
849	The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. 2020 , 13,	11
848	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. 2020 , 9, 2120-2136	4

847	Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy. 2020 , 9, 2097-2112	0
846	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. 2021 , 22, e555-e562	1
845	FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression. 2020 , 9, 2165-2172	
844	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. 2020 , 9, 2059-2073	6
843	The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. 2020 , 27, e486-e494	7
842	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. 2020 , 11, 527750	3
841	Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. 2020 , 8, e00685	1
840	The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies. 2020 , 9, e1215	9
839	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. 2020 , 25, 100249	
838	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. 2020 , 8,	2
837	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. 2020 , 37, 111	2
836	Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report. 2020 , 99, e22933	2
835	Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research. 2020 , 10, 568174	7
834	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). 2020 , 20, 1185	24
833	Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases. 2020 , 10, 568081	0
832	The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. 2020 , 10, 569202	9
831	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. 2020 , 12,	13
830	Première ligne des CBNPC avancés sans addiction oncologique : quel traitement pour quel patient ?. 2020 , 12, 2S329-2S338	

829	Tolerance of immunotherapy in combination in non-small cell lung cancer. 2020 , 12, 2S344-2S351	
828	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. 2020 , 8,	5
827	Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. 2020 , 12, 1758835920970049	7
826	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. 2020 , 12, 1758835920952994	9
825	Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. 2020 , 13, 1003-1009	10
824	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. 2020 , 10, 570080	2
823	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. 2020 , 8,	8
822	Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine. 2020 , 19, 1063-1068	1
821	Reply to: Problems With the Recommendations for PD-L1 Biomarker Testing. 2020 , 28, e65-e67	
820	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. 2020 , 8, 1243-1250	53
819	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). 2020 , 12, 1758835920915983	2
818	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. 2020 , 12, 1758835920940927	5
817	NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. 2020 , 12, 5975-5985	3
816	Immunoradiotherapy as An Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent. 2020 , 12,	12
815	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. 2020 , 383, 640-649	283
814	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. 2020 , 89, 102085	22
813	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. 2020 , 87, 106770	2
812	IMpower 131: The Exception to the Rule. 2020 , 15, 1258-1260	1

811	Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. 2020 , 23, 918-927	3
810	Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. 2020 , 25, 353-366	1
809	Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study. 2020 , 2020, 4784701	4
808	TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. 2020 , 9, 6694-6709	11
807	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. 2020 , 123, 874-884	4
806	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective. 2020 , 11, 1508	30
805	Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?. 2020 , 12,	3
804	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. 2020 , 9, 6576-6585	7
803	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. 2020 , 22, 98	2
802	PD-L1 Expression Affects Neoantigen Presentation. 2020 , 23, 101238	1
801	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. 2020 , 21, 69	10
800	Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?. 2020 , 15, 489-492	0
799	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. 2020 , 12, 1758835920937612	27
798	Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. 2020 , 20, 707	11
797	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. 2020 , 13, 105	17
796	Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience. 2020 , 28, 237-248	0
795	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naïve non-squamous non-small cell lung cancer: a phase II clinical study. 2020 , 147, 229-236	3
794	B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma. 2020 , 216, 153134	5

793	Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. 2020 , 16, 299-304	4
792	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. 2020 , 151, 141-148	24
791	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. 2021 , 17, 178-185	12
790	Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. 2020 , 38, 3129-3137	30
789	Relationship between SP142 PD-L1 Expression and F-FDG Uptake in Non-Small-Cell Lung Cancer. 2020 , 2020, 2010924	3
788	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. 2020 , 9, 17	13
787	Complete response to pembrolizumab in a patient with extensive-stage small-cell lung cancer: a case report. 2020 , 9, 2347-2352	1
786	Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation. 2020 , 7, 574759	2
785	Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. 2020 , 11, 2812-2819	7
784	Immune Oncology Biomarkers in Lung Cancer: an Overview. 2020 , 22, 107	2
783	Medical management of brain metastases. 2020 , 2, vdaa015	6
782	Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer. 2020 , 133, 2630-2632	0
781	ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. 2020 , 149, 10-16	3
780	Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma: Case report. 2020 , 66, 477-483	1
779	Using electronic health record data to identify comparator populations for comparative effectiveness research. 2020 , 23, 1618-1622	3
778	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. 2020 , 9, 1824645	11
777	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. 2020 , 11, 3585-3595	9
776	Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma. 2020 , 13, 10075-10085	3

775	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. 2020 , 10, 556275	2
774	Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy. 2020 , 91, 102116	6
773	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. 2020 , 10, 568939	6
772	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. 2020 , 12,	7
771	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. 2020 , 12,	15
770	Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. 2020 , 40, 5277-5283	10
769	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of -mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8 T Cells. 2020 , 12,	3
768	Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer. 2020 , 4, 769-783	1
767	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. 2020 , 126, 5040-5049	3
766	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. 2020 , 78, 100788	1
765	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. 2020 , 8, 35	41
764	Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer. 2020 , 21, 2185-2194	
763	Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. 2020 , 383, 944-957	214
762	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. 2020 , 50, 1447-1453	5
761	Tracking the tail. 2020 , 8,	3
760	Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy. 2020 , 9, 1015-1028	5
759	Survival analysis using a 5-step stratified testing and amalgamation routine (5-STAR) in randomized clinical trials. 2020 , 39, 4724-4744	1
758	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. 2020 , 10, 576314	6

757	Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. 2020 , 1874, 188420	9
756	Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era. 2020 , 12, 4527-4530	0
755	Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression. 2020 , 149, 23-32	6
754	Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. 2020 , 3, e2011818	10
753	Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice. 2020 , 42, 1682-1698.e7	6
752	Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. 2021 , 105, 1263-1271	13
751	Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. 2020 , 11, 3001-3006	2
750	An update on the immune landscape in lung and head and neck cancers. 2020 , 70, 505-517	33
749	A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. 2020 , 15, 1935-1942	19
748	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. 2020 , 22, 116	5
747	Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. 2020 , 146, 3269-3279	9
746	Tumor metabolic volume by F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥50. 2020 , 10, 14990	6
745	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. 2020 , 10, 10838-10848	18
744	ctDNA Concentration, MIK167 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. 2020 , 10, 1706	6
743	Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. 2020 , 18, 275	13
742	Lung cancer in women in 21th century. 2020 , 12, 4398-4410	6
741	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. 2020 , 10, 554313	13
740	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. 2020 , 14, 1179554920951358	8

739	Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. 2020 , 10, 1167	5
738	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. 2020 , 10, 1677	11
737	Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. 2020 , 38, 3863-3873	40
736	Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. 2020 , 20, 240	6
735	PD-L1 in Lung Adenocarcinoma: Insights into the Role of F-FDG PET/CT. 2020 , 12, 6385-6395	3
734	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. 2020 , 3, e2012534	26
733	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. 2020 , 12, 3796-3803	6
732	miR-502-5p affects gastric cancer progression by targeting PD-L1. 2020 , 20, 395	7
731	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. 2020 , 17, 547-556	6
730	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. 2020 , 26, 5477-5486	12
729	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. 2020 , 12,	18
728	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. 2020 , 21,	6
727	Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. 2020 , 27, 1073274820977200	2
726	PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. 2020 , 12, 1758835920965840	5
725	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. 2020 , 11, 595655	3
724	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting. 2020 , 12,	2
723	Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. 2020 , 12,	14
722	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. 2020 , 2020, 6717912	7

721	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. 2020 , 21,	3
720	Patients With -Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study. 2020 , 1, 100006	3
719	Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer. 2020 , 10, 21360	6
718	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. 2020 , 4, 32	8
717	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. 2020 , 26, 485-495	3
716	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. 2020 , 1-27	6
715	Changing paradigm in advanced and metastatic non-small cell lung cancer. 2020 , 12, 6992-7001	2
714	Biomarkers for predicting the efficacy of immune checkpoint inhibitors.. 2022 , 13, 481-495	1
713	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.. 2022 , 2, 55-63	0
712	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.. 2021 , 162, 1-10	2
711	IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.. 2021 , 7, 100353	3
710	First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.. 2021 , 7, 100355	1
709	Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies.. 2022 , 162, 158-160	0
708	Lungenkarzinom: Mehr Optionen für Patienten im fortgeschrittenen Stadium.	
707	Progress in Immunotherapy of Lung Squamous Cell Carcinoma. 2021 , 11, 6054-6060	
706	Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.. 2021 ,	2
705	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.. 2022 , 11,	4
704	Cisplatin Promotes the Efficacy of ICI Therapy by Inducing Ferroptosis and Activating Neutrophils.	

703	PHD3 as a Prognosis Marker and its relationship with Immune Infiltration in Lung Adenocarcinoma.. 2022,	
702	Preclinical Pharmacokinetics and Dosimetry of an Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.. 2021, 8, 741855	
701	Research progress of tumor targeted drug delivery based on PD-1/PD-L1.. 2022, 616, 121527	2
700	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. 2022, 15, 6	4
699	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.. 2022, 6, 2	3
698	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study.. 2022,	1
697	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50 .. 2021, 12, 803626	
696	Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy.. 2022, 11, e1363	0
695	Impact of the Economic Status of the Patient's Country of Residence on the Outcome of Oncology Clinical Trials.. 2022, 27, e244-e250	
694	Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care. 2021, 109, 98-98	0
693	Effects of Different Factors on the Efficacy of Anti PD-(L)1 Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer: An Observational, Retrospective Cohort Study.	
692	Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.. 2022, 16, 123-135	0
691	NLRP4 negatively regulates type I interferon response and influences the outcome in anti-PD-1/PD-L1 therapy.. 2021,	1
690	KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.. 2022, 16, 17534666211066064	
689	Continuation of pembrolizumab with additional chemotherapy after progression with PD-1/PD-L1 inhibitor monotherapy in patients with advanced NSCLC.. 2022,	2
688	Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.. 2022,	0
687	MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.. 2022,	7
686	Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.. 2022, 1	0

685	Complications following novel therapies for non-small cell lung cancer.. 2022,	0
684	Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.. 2022,	4
683	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.. 2022, 10,	2
682	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.. 2022, 13, 761046	2
681	Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.. 2022, 13, 257-270	
680	A Case of Pembrolizumab-induced Focal Pancreatitis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration.. 2022,	0
679	Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab.. 2022,	0
678	Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.. 2022,	2
677	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.. 2022, 28, 368-377	5
676	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.. 2022, 6, 243-255	0
675	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.. 2022, JCO2101626	8
674	Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.. 2022, 13, 877-889	0
673	Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data. 2022, 12, 1563	1
672	Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis. 2021	3
671	Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.. 2022, 1	0
670	The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.. 2022, 1	2
669	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1.. 2021, 12, 806043	1
668	BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.. 2022, 12, e718	2

667	Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.. 2022 , JCO2101639	2
666	Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer.. 2022 , 2022, 2698190	1
665	Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review.. 2022 , 29, 479-489	1
664	Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.. 2022 , 14, 427-435	0
663	Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.. 2022 ,	1
662	Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer.. 2022 , 17, 179-181	1
661	Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility.. 2022 ,	0
660	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.. 2022 , 170, 103596	0
659	Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.. 2021 , 165, 10-17	
658	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.. 2021 , 165, 71-81	0
657	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.. 2022 , 236, 108111	6
656	Immunotherapy resistance of lung cancer.. 2022 , 5, 114-128	
655	Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.. 2022 , 14, 17588359211058391	
654	OUP accepted manuscript.	
653	Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.. 2022 , 7,	2
652	Correlates With the Prognosis and Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.. 2022 , 9, 758974	0
651	T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues.. 2022 , 2022, 2381018	
650	Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer.. 2022 ,	1

649	Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.. 2022 , 12, 769124	2
648	Immunotherapy in Lung Cancer: Current Landscape and Future Directions.. 2022 , 13, 823618	2
647	Classical mathematical models for prediction of response to chemotherapy and immunotherapy.. 2022 , 18, e1009822	1
646	Can the Kuznetsov Model Replicate and Predict Cancer Growth in Humans?.	
645	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
644	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).. 2022 , 166, 107-113	0
643	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.. 2022 , 166, 84-93	0
642	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.. 2021 , 10,	0
641	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. 2021 ,	1
640	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.. 2021 , 11,	2
639	NSCLC Immunotherapy and Related Rare Toxicities: A Monocentric Real-Life Experience. 2021 , 4, 115-119	
638	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.. 2022 , 10, 441	0
637	Long-term control of generalized lung cancer with pembrolizumab. 2021 , 14, 171-174	
636	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.. 2022 , 22, e2	8
635	Research progress in immunotherapy of NSCLC with EGFR sensitive mutations.. 2022 ,	
634	First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for -altered NSCLC: a retrospective real-world POLISH study.. 2022 , 14, 17588359221082339	1
633	Non-Small Cell Lung Cancer in Older Adults with Frailty. 2022 , 319-339	
632	Neurological complications of lung cancer. 2022 , 243-276	

631	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer.. 2022 , 24, e16	1
630	Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.. 2022 , 29, 1073274822107668	0
629	Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review.. 2022 ,	0
628	Biomarkers of response to PD-1 pathway blockade.. 2022 ,	2
627	Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.. 2022 , 11, 173-187	1
626	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.. 2022 , 10,	0
625	Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.. 2022 , 11, 201-212	3
624	Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data.. 2022 ,	6
623	A Study on Immune Cell Infiltration in Lung Adenocarcinoma.. 2022 ,	0
622	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy.. 2022 , 12, 847350	1
621	Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer.. 2022 , 47,	0
620	Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in mutated non-small cell lung cancer with , or comutations: subgroup results from the phase III IMpower150 trial.. 2022 , 10,	1
619	Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.. 2022 , 14,	3
618	Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and Fusion-Which Path Should We Follow? Case Reports and Literature Review.. 2022 , 11,	0
617	A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma.. 2022 ,	2
616	Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.. 2022 , 1	1
615	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.. 2022 , 23,	2
614	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.. 2021 , 12, 749461	1

613	Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.. 2022 , 11, 11	3
612	A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression.. 2022 , 11,	0
611	Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis.. 2022 ,	1
610	Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer.	
609	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.. 2022 , 14,	
608	Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.. 2022 , 22, 255	1
607	Anti-drug antibodies in the current management of cancer.. 2022 , 1	0
606	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.. 2022 ,	4
605	CMTM6 as a master regulator of PD-L1.. 2022 , 1	1
604	Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance.. 2022 , 10, 818453	2
603	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8 T cell responses.. 2022 , 55, 512-526.e9	6
602	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. 2022 , 11,	1
601	The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study.. 2022 ,	0
600	Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.. 2022 , 14,	0
599	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-analysis of 22 randomized controlled trials.. 2022 ,	
598	NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer.	
597	Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.. 2022 , 17, 341-344	
596	First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.. 2022 ,	0

595	The clinical and prognostic significance of CMTM6/PD-L1 in oncology.. 2022 , 1	
594	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases.. 2022 , 13, 854967	2
593	The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.. 2022 ,	1
592	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review.. 2022 ,	1
591	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.. 2022 ,	0
590	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma.. 2022 , 18, 101367	1
589	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.. 2022 , 13, 830631	3
588	TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy.. 2022 , 12, 860563	4
587	Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.. 2022 , 166, 205-220	0
586	Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors.. 2022 ,	
585	Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.. 2022 ,	0
584	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.. 2022 , 19, 101383	0
583	Interleukin-1 (IL-1) and the inflammasome in cancer.. 2022 , 153, 155850	6
582	Effect of kangai injection combined with platinum-based chemotherapy on the immune function of patients with advanced non-small-cell lung cancer: A meta-analysis.. 2022 , 100, 154088	0
581	The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients. 2021 , 6, 103-108	
580	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.. 2021 , 14,	2
579	The multi-specific V-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.. 2021 ,	1
578	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.. 2021 , 22,	2

577	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.. 2021 , 23,	1
576	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.. 2021 , 14,	0
575	B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.. 2021 ,	2
574	Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis.. 2021 , 2021, 5125643	
573	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.. 2021 , 14, 109	2
572	Genomics and Prognosis Analysis of N-Methyladenosine Regulators in Lung Adenocarcinoma.. 2021 , 12, 746666	
571	Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.. 2021 , 2021, 3273347	0
570	Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report.. 2021 , 9, 11419-11424	0
569	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
568	A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.. 2021 , 12, 813331	0
567	Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy.. 2021 , 9, 1801	3
566	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. 2021 , 13,	2
565	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.. 2021 , 13,	2
564	Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. 2021 , 11, e047663	
563	Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer.. 2021 , 10781552211061117	
562	Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It.. 2021 , 22,	4
561	Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1 and immune desert-like mouse tumors.. 2022 , 47,	1
560	Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).. 2021 , 45,	0

559	Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer.. 2021 , 4, e2137508	5
558	Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications.	0
557	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. 2021 , 4, 258-270	0
556	A novel immune-related long non-coding RNAs risk model for prognosis assessment of lung adenocarcinoma.. 2021 , 13, 25550-25563	0
555	Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma.. 2021 , 10, 5212-5221	0
554	Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. 2021 , 12, CD011300	1
553	The relationship between different subtypes of and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients.. 2022 , 11, 213-223	0
552	Role of in -positive non-small cell lung cancer.. 2022 , 23, 181	
551	The use of immunotherapy in older patients with advanced non-small cell lung cancer.. 2022 , 106, 102394	1
550	Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.. 2022 , 14,	1
549	Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.. 2022 , 20, 120	0
548	Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report. 2022 , 10, 3801-3807	0
547	Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.. 2022 ,	0
546	EGFR signaling pathway as therapeutic target in human cancers.. 2022 ,	1
545	Limited role of mutation in guiding immunotherapy in advanced non-small-cell lung cancer.. 2022 ,	1
544	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.. 2022 , 5, e227722	1
543	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.. 2022 , 22, 407	0
542	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review.. 2022 , 14,	0

- 541 Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.. **2022**, 13, 875330 1
- 540 High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.. **2022**, 13, 866561 0
- 539 Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.. **2022**, 78, 102149
- 538 Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.. **2022**, 7, 100465 3
- 537 Data_Sheet_1.zip. **2020**,
- 536 Image_1.JPEG. **2020**,
- 535 Image_2.JPEG. **2020**,
- 534 Image_3.JPEG. **2020**,
- 533 Image_4.JPEG. **2020**,
- 532 Data_Sheet_1.docx. **2020**,
- 531 Data_Sheet_1.docx. **2020**,
- 530 Table_1.xls. **2020**,
- 529 Data_Sheet_1.docx. **2020**,
- 528 Data_Sheet_1.pdf. **2019**,
- 527 Image_1.pdf. **2019**,
- 526 Image_2.pdf. **2019**,
- 525 Image_3.pdf. **2019**,
- 524 Image_4.pdf. **2019**,

523 Image_5.pdf. 2019,

522 Image_6.pdf. 2019,

521 Image_7.pdf. 2019,

520 Image_8.pdf. 2019,

519 Table_1.XLSX. 2019,

518 Table_2.XLSX. 2019,

517 Table_3.XLSX. 2019,

516 Table_4.XLSX. 2019,

515 Table_5.XLSX. 2019,

514 Table_6.XLSX. 2019,

513 Table_7.XLSX. 2019,

512 Table_8.XLSX. 2019,

511 DataSheet_1.csv. 2020,

510 Image_1.tif. 2020,

509 Image_2.tif. 2020,

508 Image_3.tif. 2020,

507 Image_4.tif. 2020,

506 Image_5.tif. 2020,

505 Image_6.tif. **2020**,

504 Image_7.tif. **2020**,

503 Image_8.tif. **2020**,

502 Image_9.tif. **2020**,

501 Data_Sheet_1.docx. **2020**,

500 Data_Sheet_1.docx. **2019**,

499 Table_1.DOCX. **2020**,

498 Table_2.DOCX. **2020**,

497 Data_Sheet_1.docx. **2019**,

496 Data_Sheet_1.PDF. **2019**,

495 Table_1.docx. **2019**,

494 Data_Sheet_1.docx. **2020**,

493 Image_1.TIF. **2020**,

492 Image_2.TIF. **2020**,

491 Table_1.xlsx. **2020**,

490 Table_2.xlsx. **2020**,

489 Table_3.xlsx. **2020**,

488 DataSheet_1.pdf. **2019**,

487 Data_Sheet_1.docx. **2018**,

486 Table_1.DOCX. **2020**,

485 Data_Sheet_1.doc. **2019**,

484 Table_1.doc. **2020**,

483 Table_2.doc. **2020**,

482 Table_3.doc. **2020**,

481 Image_1.TIF. **2019**,

480 Image_2.TIFF. **2019**,

479 Image_3.TIF. **2019**,

478 Table_1.DOCX. **2019**,

477 Table_10.DOCX. **2019**,

476 Table_11.DOCX. **2019**,

475 Table_12.docx. **2019**,

474 Table_2.DOCX. **2019**,

473 Table_3.DOCX. **2019**,

472 Table_4.DOCX. **2019**,

471 Table_5.docx. **2019**,

470 Table_6.DOCX. **2019**,

469 Table_7.DOCX. 2019,

468 Table_8.DOCX. 2019,

467 Table_9.DOCX. 2019,

466 Table_1.docx. 2020,

465 Data_Sheet_1.zip. 2020,

464 Data_Sheet_1.docx. 2020,

463 Table_1.XLSX. 2020,

462 Data_Sheet_1.docx. 2018,

461 DataSheet_1.pdf. 2019,

460 Data_Sheet_1.PDF. 2019,

459 Table_1.pdf. 2019,

458 [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer]. 2021, 24, 777-783

2

457 [Progress of Immune Checkpoint Inhibitors ?in the Treatment of Advanced Pulmonary Neuroendocrine Tumors]. 2021, 24, 784-789

456 [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].. 2022, 25, 46-53

455 [Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction ?of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].. 2022, 25, 92-101

454 Deubiquitination and Stabilization of PD-L1 by USP21.. 2021, 13, 12763-12774

453 The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.. 2022, 5, 31-45

452 Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.. 2022, 16, 11795549221092747

0

451	Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.. 2022 , 11, 670-685	0
450	as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma.. 2022 , 12, 867788	1
449	Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.. 2022 , 13, 829634	0
448	Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 2022 , 15, 533	1
447	A New AI-assisted Scoring System for PD-L1 expression in NSCLC. 2022 , 106829	0
446	Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.. 2022 , 1	0
445	Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway.. 2022 , 1-5	
444	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. 2022 , 14,	1
443	[Management of immune-related adverse events (irAEs) - what needs to be respected?]. 2022 , 55, 1-6	1
442	Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. 2022 , 13,	0
441	ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.. 2022 , 20, 170	1
440	Real-World Progression-Free Survival as an Endpoint in Advanced Non-Small-Cell Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Data Derived From Electronic Health Records.	0
439	Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. 2022 , 14,	2
438	Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies. 2022 , 12,	1
437	Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis.. 2022 , 105403	
436	Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.. 2022 ,	0
435	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials.. 2022 , 174, 103700	0
434	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.. 2022 , 12, 876098	0

433	Different Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.. 2022 , 2022, 8513747	0
432	Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.. 2022 , 10, e00941	
431	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).. 2022 , 1	
430	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.. 2022 , 7, 100474	1
429	Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.. 2022 , 170, 17-26	1
428	Crosstalk of Immuno-Oncology and Metabolism: Influence of Akkermansia muciniphila and Personalized Therapy Approach. 2022 , 91-115	
427	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. 2022 , 13,	1
426	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma.. 2022 , 12, 8230	
425	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.. 2022 , 10,	1
424	Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. 2022 ,	3
423	Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. 2022 ,	0
422	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. 2022 , 13,	1
421	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. 2022 , 12,	0
420	Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India. 2022 ,	
419	High-Resolution Single-Cell Atlas Reveals Diversity and Plasticity of Tissue-Resident Neutrophils in Non-Small Cell Lung Cancer.	0
418	HLA-I diversity and Tumor Mutational Burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. 2022 ,	0
417	Traitement de 1re ligne des CBNPC métastatiques sans addiction oncogénique. 2022 , 14, 1S52-1S67	
416	Immune checkpoint inhibitors alone vs immune checkpoint inhibitors combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.	0

415	Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next-generation sequencing.	0
414	High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.	0
413	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation TherapyâProof-of-Concept Animal Study. 2022 , 10, 1173	0
412	Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC. 2022 , 14, 2626	1
411	Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.	0
410	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. 12,	0
409	Versatile tests for window mean survival time.	0
408	Development of Two Diagnostic Prediction Models for Leptomeningeal Metastasis in Patients With Solid Tumors. 2022 , 13,	
407	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced NonâSmall-Cell Lung Cancer Previously Treated With ImmunotherapyâLung-MAP S1800A.	4
406	Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.	1
405	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. 2022 , 10, e004440	1
404	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for NonâSquamous Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. 2022 , 100355	0
403	Immunomodulation in Autoimmune Disorders. 2022 , 303-327	0
402	PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. 2022 , 29, 107327482211075	0
401	Tumoral and Stromal Pdl1 and Pdl2 Checkpoints Immunohistochemical Expression in Pancreatic Ductal Adenocarcinoma, a Promising Field Of Study. 2022 , 10, 775-781	
400	Modern treatment of ALK-positive non-small cell lung cancer. 2022 , 3, 41-51	
399	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. 12,	
398	Brief Report: Safety and Anti-Tumor Activity of Alectinib Plus Atezolizumab from a Phase 1b Study in Advanced ALK-Positive NSCLC. 2022 , 100367	0

- 397 First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer.
- 396 A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. 1
- 395 MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. 1
- 394 Radiopharmaceuticals as Novel Immune System Tracers. **2022**, 100936
- 393 Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer. **2022**, 22,
- 392 Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. Volume 15, 637-642 0
- 391 Pneumonitis after Stereotactic Thoracic Radioimmunotherapy with Checkpoint Inhibitors: Exploration of the DoseâVolumeâEffect Correlation. **2022**, 14, 2948
- 390 First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score â50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). 1
- 389 Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive Non-Small-Cell Lung Cancer undergoing immune checkpoint inhibitors as second-line therapy. 1-31
- 388 Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. 13, 1
- 387 PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. **2022**, 12, 1
- 386 Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. **2022**, 11, 3245 1
- 385 Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression. 1-13
- 384 Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. thoraxjnl-2020-215614 0
- 383 Treatment Considerations for Patients with Advanced Squamous Cell Carcinoma of the Lung. **2022**, 1
- 382 A phase 2 study of docetaxel, ramucirumab, and pembrolizumab for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.. **2022**, 0
- 381 Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. Volume 14, 2079-2090 0
- 380 Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation). **2022**, 186-192

- 379 Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. 1
- 378 Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy. **2022**, 17, 865-866
- 377 Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. **2022**, 176, 103746
- 376 Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. **2022**, 172, 85-95 2
- 375 The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. **2022**, 34, 64-77
- 374 ICIs-Related Cardiotoxicity in Different Types of Cancer. **2022**, 9, 203 0
- 373 Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. 0
- 372 A review of concurrent chemo/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181. **2022**,
- 371 Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting. 12,
- 370 Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. 12,
- 369 Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Publish Ahead of Print,
- 368 Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods. 13, 1
- 367 Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. 0
- 366 Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. **2022**, 22,
- 365 Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
- 364 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. 1
- 363 Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer. 0
- 362 The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer. 0

361	Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study.	0
360	Clinically-meaningful improvements in therapy for unresectable NSCLC.	0
359	A patient with stage IV adenocarcinoma harboring an EGFR mutation who survived for about 10 years following salvage surgery after molecular targeting drug therapy and chemotherapy. 2022 , 36, 504-510	
358	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.	0
357	Pulmonary adverse events following immune checkpoint inhibitors. Publish Ahead of Print,	0
356	TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. 2022 , 14, 3382	
355	Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. 2022 , 13,	0
354	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. 2022 , 22,	0
353	HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. 2022 , 22,	0
352	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. 2022 , 14, 3473	1
351	Exploring immunotherapy in colorectal cancer. 2022 , 15,	5
350	Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination. 12,	1
349	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. 2022 , 14, 3337	2
348	Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.	
347	Generation, secretion and degradation of cancer immunotherapy target PD-L1. 2022 , 79,	0
346	Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes. 2022 , 14, 3472	1
345	General independent censoring in event-driven trials with staggered entry.	1
344	The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer. 2022 , 89, 120-127	0

- 343 Applicability analysis of immunotherapy for lung cancer patients based on deep learning. **2022**, 205, 149-156
- 342 Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. **2022**, 110, 108968 1
- 341 Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. **2022**, 171, 3-8
- 340 Lung Cancer. **2023**, 57-78
- 339 Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. 0
- 338 The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. 1
- 337 Effets indésirables rhumatologiques des inhibiteurs de point de contrôle PD-(L)1 dans le cancer du poumon : revue systématique et méta-analyse. **2022**,
- 336 Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. 12, 0
- 335 Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13, 0
- 334 Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. 0
- 333 PD-1⁺ TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. 0
- 332 Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
- 331 Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. **2022**, 10, 8284-8290 0
- 330 Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients. **2022**, 10, 0
- 329 Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. 13,
- 328 Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. 12, 0
- 327 Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12, 2
- 326 Fatal pneumonitis associated with immune checkpoint inhibitors: a study based on 128 cohorts with 26,994 participants.

325	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. 12,	1
324	Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?. 13,	0
323	Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. 13,	
322	Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. 2022 , 5, e2227211	0
321	Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. 12,	
320	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. 13,	0
319	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. 2022 , 12, 1229	
318	The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study.	
317	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. 2022 , 23, 9391	0
316	Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer. 2022 , 23, 8878	0
315	Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. 2022 , 33, 752-757	
314	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12,	2
313	Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients. 12,	0
312	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.	
311	Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. 13,	1
310	Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report. 2022 , 101, e30099	0
309	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
308	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. 9,	0

307	Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.	2
306	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 $\geq 50\%$. 12,	1
305	Immunotherapeutic targets in non-small cell lung cancer.	1
304	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. 2022, 2022, 1-15	
303	The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. 2022, 2022, 1-11	
302	Computational design of PD-L1 small molecule inhibitors for cancer therapy.	2
301	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. 2022,	0
300	Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis. 13,	1
299	PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with $\geq 1\%$ PD-L1 expression: a meta-analysis of randomized controlled trials.	0
298	Integrative Analysis of Bioinformatics and Machine Learning Algorithms Identifies a Novel Diagnostic Model Based on Costimulatory Molecule for Predicting Immune Microenvironment Status in Lung Adenocarcinoma. 2022,	
297	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. 2022, 12, 653-671	1
296	Venous thromboembolism in cancer and cancer immunotherapy. 2022, 178, 103782	0
295	Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. 2022, 172, 65-74	0
294	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. 2022, 7, 100577	0
293	Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. 2022, 14, 1121-1131	0
292	Novel and existing flexible survival methods for network meta-analyses. 2022, 11, 1121-1133	0
291	Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. 2022, 179, 103806	0
290	Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. 2022, 173, 101-106	0

- 289 Dermatology (Skin). **2022**, 29-58 ○
- 288 Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. **2022**, ○
- 287 Available Immunotherapy Drugs in Oncology. **2022**, 5-23 ○
- 286 Pulmonology (Lung). **2022**, 275-299 ○
- 285 Immune checkpoint inhibitor-induced arthralgia is tightly associated with improved overall survival in cancer patients. ○
- 284 Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor. **2022**, 18, 3031-3041 ○
- 283 NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. **2022**, 40, 1027-1043.e9 2
- 282 Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review. 12, ○
- 281 PD-L1 / PD-L1 signalling promotes colorectal cancer cell migration ability through RAS / MEK / ERK. ○
- 280 Combating pancreatic cancer with ovarian cancer cells. ○
- 279 Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. 12, ○
- 278 Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. 13, ○
- 277 Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms. 13, ○
- 276 Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. 12, ○
- 275 Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China. Volume 15, 1021-1032 ○
- 274 Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. **2022**, 7, 2
- 273 Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. **2022**, 11, 5171 ○
- 272 Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. 13, ○

- 271 Integration of New Systemic Adjuvant Therapies for Non-Small Cell Lung Cancer: Role of the Surgeon. **2022**, 0
- 270 The Interaction of the IFN γ /JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. **2022**, 2022, 1-16 0
- 269 EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. **2022**, 22, 0
- 268 The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. 13, 5
- 267 The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. 0
- 266 The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis. 13, 0
- 265 On-Target Side Effects of Targeted Therapeutics of Cancer. 28, 0
- 264 Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. **2022**, 101, e30151 0
- 263 Can the Kuznetsov Model Replicate and Predict Cancer Growth in Humans?. **2022**, 84, 0
- 262 Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis. 0
- 261 The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression. 12, 0
- 260 Transcriptome Analysis of Human Endogenous Retroviruses at Locus-Specific Resolution in Non-Small Cell Lung Cancer. **2022**, 14, 4433 0
- 259 Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. 8
- 258 Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review. 030089162211226 0
- 257 Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer. 0
- 256 Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials. 13, 0
- 255 Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. OF1-OF1 0
- 254 Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial. **2022**, 0

253	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. 1-34	0
252	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. 1-12	0
251	Monoclonal antibodies in cervical malignancy-related HPV. 12,	0
250	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. 12,	1
249	Bifidobacterium breve predicts the efficacy of anti-PD -1 immunotherapy combined with chemotherapy in Chinese NSCLC patients.	0
248	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. 13,	1
247	Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer. 2022 , 173, 107-115	0
246	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. 2022 ,	0
245	Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy.	0
244	An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.	0
243	Synthesis and preliminary evaluations of [18F]fluorinated pyridine-2-carboxamide derivatives for targeting PD-L1 in cancer. 2022 , 23,	0
242	History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. 2022 , 73, 325-331	0
241	Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. 2022 ,	0
240	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic Driven Non-Small Cell Lung Cancer: A University of California Lung Cancer Consortium Retrospective Study. 2022 , 100427	0
239	Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. 1-8	0
238	Longitudinal assessment of ROPRO as an early indicator of overall survival in oncology clinical trials: a retrospective analysis.	0
237	Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. 2022 , 22,	1
236	Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer.	0

- 235 Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. Publish Ahead of Print, 0
- 234 Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé?. **2022**, 14, 2S225-2S232 0
- 233 Algorithme thérapeutique des cancers bronchiques non à petites cellules tendus avec mutation de l'EGFR. **2022**, 14, 2S189-2S208 0
- 232 Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. 12, 1
- 231 The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do not Receive Chemoradiation. Publish Ahead of Print, 0
- 230 Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment. 630-642 1
- 229 Traitements systémiques du cancer bronchique non à petites cellules chez les sujets âgés. **2022**, 14, 2S327-2S337 0
- 228 Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?. **2022**, 11, 3280 0
- 227 Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors. 0
- 226 Precision Medicine in Oncology Drug Development. 1-15 0
- 225 Biomarker-Targeted Therapies in Non-small Cell Lung Cancer: Current Status and Perspectives. **2022**, 11, 3200 0
- 224 Cancer of the Lung. 1-29 0
- 223 Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: a systematic review and Meta-analysis. 0
- 222 Algorithme thérapeutique des CBNPC sans mutation addictive. **2022**, 14, 2S165-2S177 0
- 221 Squamous cell lung cancer: Current landscape and future therapeutic options. **2022**, 0
- 220 Predictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer. **2022**, 62, 355-362 0
- 219 Circ_0084043-miR-134-5p axis regulates PCDH9 to suppress melanoma. 12, 0
- 218 Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. 9, 0

217	Analyse de la prise en charge des cancers bronchiques avec mutation du gène de l'EGFR. 2022,	0
216	Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. 2022, 14, 4974	2
215	Inmunoterapia en pacientes con cáncer de pulmón y metástasis cerebrales de inicio. 2022, 25,	0
214	Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer.	0
213	Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. 2022, 16,	0
212	Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.	0
211	The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?.	0
210	Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment. 2022, 5, e2239874	0
209	Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. 2022, 7, 100593	0
208	Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. 2022, 174, 45-49	0
207	RAS: Circuitry and therapeutic targeting. 2023, 101, 110505	0
206	Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. 2022, 8, 27	0
205	Datele din lumea reală - studiiile clinice pentru evaluarea eficacității noilor terapii oncologice. Rolul studiilor observaționale, cu exemplificare în cancerul pulmonar frântelule mici (NSCLC). 2022, 3, 23	0
204	Drug Resistance in Lung Cancer. 2022,	0
203	Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. 13,	0
202	Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. 12,	0
201	Single-cell RNA sequencing reveals cellular and molecular reprogramming landscape of gliomas and lung cancer brain metastases. 2022, 12,	0
200	Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. 2022, 2022, 1-15	0

- 199 A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. **2022**, 22, ○
- 198 PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma. 12, ○
- 197 Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. **2022**, 14, ○
- 196 Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). ○
- 195 KRAS in NSCLC: State of the Art and Future Perspectives. **2022**, 14, 5430 ○
- 194 ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. 1
- 193 Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. **2022**, 23, 13723 ○
- 192 Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. 12, ○
- 191 Editorial: Impact of immunotherapy in lung cancer. 12, ○
- 190 Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. **2022**, 20, ○
- 189 The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. 1
- 188 High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. **2022**, 1
- 187 Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. **2022**, ○
- 186 Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. 1
- 185 A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. **2022**, 101, e31751 ○
- 184 Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. **2022**, 14, 5649 ○
- 183 The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. **2022**, ○
- 182 Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. **2022**, 14, 175883592211440 ○

181	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.	0
180	Design and reporting of phase III oncology trials with prospective biomarker validation.	0
179	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. 13,	1
178	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. 2022, 24, 269-304	0
177	Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer. 2022, 10, e005581	1
176	Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. 2022, 12,	1
175	Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. 13,	0
174	[Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer.	0
173	The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy. Volume 14, 3485-3492	1
172	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. 13,	0
171	Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. 2022, 10, e005436	0
170	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. 2022, 22,	0
169	First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia. 2022, 12-20	0
168	Noninvasive Imaging of Tumor PD-L1 Expression Using [99mTc]Tc-Labeled KN035 with SPECT/CT.	0
167	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. 2022, 22,	2
166	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.	0
165	A novel diagnostic model for predicting immune microenvironment subclass based on costimulatory molecules in lung squamous carcinoma. 13,	0
164	Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.	0

- 163 Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. **2022**, 7, 100630 ○
- 162 Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis. 1-11 ○
- 161 Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. **2022**, 10, e004952 ○
- 160 Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease. ○
- 159 Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. **2022**, ○ 1
- 158 Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. 12, ○
- 157 Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. **2022**, 14, 6145 ○
- 156 Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. **2022**, 100934 ○
- 155 Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study. ○
- 154 Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. **2022**, 3, ○
- 153 Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center. ○
- 152 MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. 13, ○
- 151 Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. 13, ○
- 150 Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study. ○
- 149 Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. **2022**, ○
- 148 Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. 12, ○
- 147 Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer. Publish Ahead of Print, ○
- 146 Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018. **2023**, 23, ○

145	Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. 1-11	0
144	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.	0
143	Mechanisms of Resistance to Immunotherapies in Cancer. 2023 , 1-30	0
142	Genomic and immunogenomic analysis of three prognostic signature genes in LUAD. 2023 , 24,	0
141	Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC. 2023 , 23,	0
140	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. 2023 , 15, 329	0
139	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. 13,	0
138	Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer. Volume 12, 1-16	0
137	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.	1
136	EGFR-Directed Therapy in Lung Cancer. 2023 ,	0
135	Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data. 12,	0
134	Thermal immuno-nanomedicine in cancer.	2
133	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. 14,	0
132	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023 ,	0
131	Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery. Volume 18, 263-276	0
130	Strahlentherapie und Immuntherapie. 2023 , 1-20	0
129	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.	0
128	Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. 2023 ,	0

- 127 Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. **2023**, 11, 190 ○
- 126 The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. ○
- 125 Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. ○
- 124 Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. **2023**, 35, 100382 ○
- 123 Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. **2023**, 857, 147177 ○
- 122 Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. ○
- 121 Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. **2023**, 15, 185 ○
- 120 Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. **2023**, 15, 180 ○
- 119 The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. **2023**, 15, 284 1
- 118 Dose Regimen Optimization of PD-L1 Inhibitor and Nab-paclitaxel in Patients with NSCLC: a Quantitative Systems Pharmacology analysis. ○
- 117 Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy. 1
- 116 Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. ○
- 115 Tumor immunology. **2023**, 245-452 ○
- 114 Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. 1-12 ○
- 113 [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. **2023**, 1-40 ○
- 112 Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective. 10, 1
- 111 Multistate models as a framework for estimand specification in clinical trials of complex processes. ○
- 110 Immunotherapy for older patients with cancer. **2023**, 17, 37-46 ○

- 109 Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. **2023**, 13, ○
- 108 Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. **2023**, 12, 191 ○
- 107 Lung Immunotherapy in the Elderly with NSCLC – The Who, the What, and the When. **2023**, ○
- 106 Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors. ○
- 105 Liquid biopsy and immunotherapy: is all that glitter gold?. **2023**, 83-117 ○
- 104 Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. 12, ○
- 103 Design of a protease-activated PD-L1 inhibitor. ○
- 102 Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. ○
- 101 Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. **2023**, 18, ○
- 100 Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors. **2023**, 15, 1382 ○
- 99 A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. **2023**, 23, ○
- 98 Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207 ○
- 97 Early CRP kinetics predicts immunotherapy response in NSCLC in the phase III OAK trial. ○
- 96 Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. **2023**, 179, 107173 ○
- 95 Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. **2023**, 1 ○
- 94 Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. 13, ○
- 93 Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. **2023**, 114, 102520 1
- 92 Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. ○

- 91 Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report. 14, ○
- 90 Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves. **2023**, 65, ○
- 89 Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. **2023**, 178, 116-122 ○
- 88 Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. **2023**, 14, ○
- 87 Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors. 13, 1
- 86 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 85 Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. **2023**, 153, 40039 ○
- 84 MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features. **2023**, 4, 46-56 ○
- 83 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 ○
- 82 Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. **2023**, 4, 100474 ○
- 81 Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports. **2023**, 32, 187-200 ○
- 80 Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward. Volume 16, 99-108 ○
- 79 Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. **2023**, 30, 2366-2387 ○
- 78 Ezrin regulates the progression of NSCLC by YAP and PD-L1. ○
- 77 Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer. **2023**, 9, 527 ○
- 76 Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. 14, ○
- 75 The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy. **2023**, 68, 86-93 ○
- 74 Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. 13, ○

73	Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. 2023 , 18, e0282020	0
72	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. 2023 , 23,	1
71	Lung cancer immunotherapy: progress, pitfalls, and promises. 2023 , 22,	0
70	Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.	0
69	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. 2023 , 11, e006464	0
68	Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy. 2023 , 1-32	0
67	Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. 2023 , 8,	0
66	Liquid Biopsies in Lung Cancer. 2023 , 15, 1430	0
65	Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). 2023 , 4, 100484	0
64	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). 2023 , 178, 191-197	0
63	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. 2023 , 12, 1833	0
62	Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians. 14,	0
61	Precision Surgery in NSCLC. 2023 , 15, 1571	0
60	Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. 2023 , 42, 112162	0
59	Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. 2023 , 8, 101160	0
58	PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis. 14,	0
57	Why Don't the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment. 2023 , 24, 5026	0
56	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14,	0

- 55 Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments. 14, ○
- 54 TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. **2023**, 4, 100494 ○
- 53 Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer. ○
- 52 Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma. ○
- 51 Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. **2023**, 12, 832 ○
- 50 Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches. 13, ○
- 49 Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. **2023**, 26, 445-453 ○
- 48 Current Advances in Immune Checkpoint Therapy. ○
- 47 DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real world approach and patient similarity network analysis. ○
- 46 Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma. 2207201 ○
- 45 Anti-PD-(L)1 therapy of non-small cell lung cancer—a summary of clinical trials and current progresses. **2023**, 9, e14566 ○
- 44 Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. 14, ○
- 43 PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers. ○
- 42 Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. **2023**, 36, 100159 ○
- 41 Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study. 13, ○
- 40 Nanomedicine in Lung Cancer Immunotherapy. 11, ○
- 39 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 ○
- 38 Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis. 14, ○

- 37 Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy. *Review.* **2023**, 24, 5858
- 36 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16,
- 35 Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice. **2023**, 12, 2409
- 34 Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. **2023**, 15, 1909
- 33 Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. 13,
- 32 Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). **2023**, 8, 101192
- 31 The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD -1/ PD-L1 inhibitors: A systematic review and meta-analysis.
- 30 Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features. **2023**, 244, 154423
- 29 Multiparameter prediction model of immune checkpoint inhibitors combined with chemotherapy for non-small cell lung cancer based on support vector machine learning. **2023**, 13,
- 28 The Value of Comprehensive Molecular Profiling in Early Stage Lung Cancer. **2023**, 18, 393-395
- 27 Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. **2023**, 9,
- 26 The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report. **2023**, 23, 230-234
- 25 Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. **2023**, 13,
- 24 Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study. 13,
- 23 Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
- 22 Clinical impact of first-line PD -1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
- 21 Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. **2023**,
- 20 Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review.

- 19 The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors. **2023**, 12, 27 ○
- 18 Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. ○
- 17 Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. 14, ○
- 16 Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker. **2023**, 23, ○
- 15 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 14 Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. ○
- 13 Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China. 13, ○
- 12 Multi-omics characterization of cellular state diversity and bidirectional tumor-stroma/immune interactions in cervical squamous cell carcinoma. ○
- 11 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○
- 10 Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. **2023**, 13, 37-43 ○
- 9 Nanotechnology-empowered lung cancer therapy: From EMT role in cancer metastasis to application of nanoengineered structures for modulating growth and metastasis. **2023**, 115942 ○
- 8 CodeBreakK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. Volume 14, 31-39 ○
- 7 Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. **2023**, 24, 7577 ○
- 6 Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. **2023**, 13, ○
- 5 Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. **2023**, 23, ○
- 4 bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. **2023**, 91, 104564 ○
- 3 Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. ○
- 2 Inside PD-1/PD-L1,2 with their inhibitors. **2023**, 256, 115465 ○

- 1 PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes. **2023**, 565, 216224

○